[COMPANY_001] Research and Development  
RTH258/brolucizumab 
Clinical Trial Protocol CRTH258A2303E1/ [STUDY_ID_REMOVED]
A
 56-week p hase IIIb/IV , open-l abel, one-arm extension 
study to assess the efficacy and safety of brolucizumab [ADDRESS_1176346] 
completed the CRTH258A2303 (TALON ) study 
Document type:  Amended  Protocol  
EUDRACT number:  2020 -002349 -40  
Version number:  02 (Clean ) 
Clinical Trial Phase:  IIIb/IV  
Release date:  20-Oct-2021
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 3.0 dated 31 -Jan-2020  
[COMPANY_001]  Confidential  Page 2 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Table of contents  
Table of contents ................................................................................................................. [ADDRESS_1176347] of abbreviations  ............................................................................................................ 6 
Glossary of terms  ................................................................................................................. 8 
Amendment 2 (20- Oct-2021) ............................................................................................ 10 
Summary of previous amendments ................................................................................... 12 
Amendment 1 (13- Aug-2021) ........................................................................................... 12 
Protocol summary  .............................................................................................................. 15 
1 Introduction ....................................................................................................................... 17 
1.1 Background ............................................................................................................ 17 
1.2 Purpose .................................................................................................................. 19 
2 Objectives and endpoints ................................................................................................... 19 
2.1 Primary estimands  ................................................................................................. 20 
2.2 Secondary estimands ............................................................................................. 21 
3 Study design ...................................................................................................................... 21 
4 Rationale ............................................................................................................................ 23 
4.1 Rationale for study design ..................................................................................... 23 
4.2 Rationale for dose/regimen and duration of treatment .......................................... 24 
4.3 Rationale for choice of control drugs (comparator/placebo) or combination drugs ...................................................................................................................... 25
 
4.4 Purpose and timing of interim analyses/design adaptations .................................. 25 
4.5 Risks and benefits .................................................................................................. 25 
5 Study population ................................................................................................................ 26 
5.1 Inclusion criteria  .................................................................................................... 26 
5.2 Exclusion criteria  ................................................................................................... 26 
6 Treatment  ........................................................................................................................... 27 
6.1 Study treatment ...................................................................................................... 27 
6.1.1 Investigational and control drugs .......................................................... 27 
6.1.2 Additional study treatments .................................................................. 28 
6.1.3 Treatment arms/group  ........................................................................... 28 
6.1.4 Treatment duration  ................................................................................ 28 
6.2 Other treatment(s)  .................................................................................................. 28 
6.2.1 Concomitant therapy  ............................................................................. 28 
6.2.2 Prohibited medication  ........................................................................... 29 
[COMPANY_001]  Confidential  Page 3 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 6.2.3 Rescue medication  ................................................................................ 30 
6.3 Participant numbering, treatment assignment, randomization  .............................. 30 
6.3.1 Participant numbering  ........................................................................... 30 
6.3.2 Treatment assignment, randomization  .................................................. 30 
6.4 Treatment blinding  ................................................................................................ 30 
6.5 Dose escalation and dose modification .................................................................. 31 
6.6 Additional treatment guidance ............................................................................... 31 
6.6.1 Treatment compliance  ........................................................................... 31 
6.7 Preparation and dispensation  ................................................................................. 31 
6.7.1 Handling of study treatment and additional treatment .......................... 31 
6.7.2 Instruction for prescribing and taking study treatment ......................... 32 
7 Informed consent procedures ............................................................................................ 35 
8 Visit schedule and assessments  ......................................................................................... 36 
8.1 Screening  ............................................................................................................... 39 
8.1.1 Information to be collected on screening failures ................................. 39 
8.2 Participant demographics/other baseline characteristics  ....................................... [ADDRESS_1176348]- study treatment  .......................................................... 48 
10 Safety monitoring and reporting  ........................................................................................ 48 
10.1 Definition of adverse events and reporting requirements ...................................... 48 
10.1.1 Adverse events ...................................................................................... 48 
10.1.2 Serious adverse events  .......................................................................... 50 
[COMPANY_001]  Confidential  Page 4 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 10.1.3 SAE reporting........................................................................................ 51 
10.1.4 Pregnancy reporting .............................................................................. 52 
10.1.5 Reporting of study treatment errors including misuse/abuse ................ 52 
10.2 Additional Safety Monitoring  ................................................................................ 52 
11 Data Collection and Database management  ...................................................................... 52 
11.1 Data collection  ....................................................................................................... 52 
11.2 Database management and quality control ............................................................ 53 
11.3 Site monitoring  ...................................................................................................... 53 
12 Data analysis and statistical methods  ................................................................................ 54 
12.1 Analysis sets .......................................................................................................... 54 
12.2 Participant demographics and other baseline characteristics  ................................. 55 
12.3 Treatments  ............................................................................................................. 55 
12.4 Analysis of the primary endpoint(s)/estimand(s) .................................................. 55 
12.4.1 Definition of primary endpoint(s)/estimand(s)  ..................................... 55 
12.4.2 Statistical model, hypothesis, and method of analysis .......................... 63 
12.4.3 Handling of remaining intercurrent events of primary estimand  .......... 63 
12.4.4 Handling of missing values not related to intercurrent event  ............... 64 
12.4.5 Sensitivity analyses for primary endpoint/estimand  ............................. 64 
12.5 Analysis of secondary endpoints/estimands  .......................................................... 64 
12.5.1 Efficacy and/or pharmacodynamic endpoint(s) .................................... 64 
12.5.2 Safety endpoints .................................................................................... 65 
  66 
12.7 Interim analyses  ..................................................................................................... 66 
12.8 Sample size calculation .......................................................................................... 66 
13 Ethical considerations and administrative procedures  ...................................................... 68 
13.1 Regulatory and ethical compliance ........................................................................ 68 
13.2 Responsibilities of the investigator and IRB/IEC  .................................................. [ADDRESS_1176349] of tables  
Table 2 -1 Objectives and related endpoints .......................................................... 19 

[COMPANY_001]  Confidential  Page 5 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Table 6 -1 Investigational drug ............................................................................... 27 
Table 6 -2 Prohibited medications and procedures  ................................................ 29 
Table 6 -3 Disease Activity assessment and treatment occurrence according to visit type  ................................................................................................ 34
 
Table 8 -1 Assessment Schedule  ............................................................................ 37 
Table 8 -2 Safety assessments  ................................................................................ 42 
Table 10-1 Guidance for capturing the study treatment errors including misuse/abuse ......................................................................................... 52
 
Table 12-1 Primary and sensitivity estimands  ......................................................... 56 
Table 12-2 Duration of intervals as estimated based on simulation studies  ............ 67 
Table 12-3 Duration of intervals as estimated based on simulation studies and 
width of 95% Confidence Interval ........................................................ 67 
Table 12-4 95% Confidence Interval for BCVA change assuming SD of the 
change is 13. .......................................................................................... [ADDRESS_1176350] of figures  
Figure 3-1 Study design .......................................................................................... 22 
Figure 6-1 Treatment regimen  ................................................................................ 32 
 
[COMPANY_001]  Confidential  Page 6 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 List of abbreviations  
AE Adverse Event  
AESI  Adverse Events of Special Interest  
AMD  Age-related  macular degeneration  
ANCOVA  Analysis of covariance  
ANOVA  Analysis of Variance  
BCVA  Best Corrected Visual Acuity  
CDP  Clinical Development Plan  
CFP Color Fundus Photography  
CFR Code of Federal Regulation  
CI Confidence Interval  
CMO&PS  Chief Medical Office and Patient Safety  
CNV  Choroidal Neovascularization  
CRC  Central Reading Center  
CRF Case Report/Record Form   
CRO  Contract Research Organization  
CSFT  Central Subfield Thickness  
DA Disease Activity  
eCRF  electronic Case Report/Record Form  
EDC  Electronic Data Capture  
EOS  End of Study  
EOT End of Treatment  
ETD Early Tre atment Discontinuation  
ETDRS  Early Treatment Diabetic Retinopathy Study  
FA Fluorescein Angiography  
FAS Full Analyses Set  
FIR First Interpretable Results  
FSH Follicle Stimulating Hormone  
GCP  Good Clinical Practice  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization of Technical Requirements for Pharmaceuticals 
for Human Use  
IEC Independent Ethics Committee  
IOI Intraocular Inflammation  
IOP Intraocular Pressure  
IRB Institutional Review Board  
IRF Intraretinal Fluid  
IRT Interactive Response Technology  
IVT Intravitreal injection  
LOCF  Last observation carried forward  
MedDRA  Medical dictionary for regulatory activities  
[COMPANY_001]  Confidential  Page 7 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 MMRM  Mixed Model for Repeated Measures  
mg milligram(s)  
mL milliliter(s)  
nAMD  neovascular Age -related Macular Degeneration  
OCT  Optical Coherence Tomography  
PDT Photodynamic Therapy  
PPS Per Protocol Set  
PRN  Pro Re Nata (as needed)  
q12w  Every [ADDRESS_1176351] Operation Procedures  
SRF Subretinal Fluid  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
T&E Treat -and-Extend  
TtC Treat -to-Control  
USM  Urgent Safety Measures  
VEGF  Vascular Endothelial Growth Factor  
 
[COMPANY_001]  Confidential  Page 8 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Glossary of terms  
Assessment  A procedure used to generate data required by [CONTACT_1758] . 
Cohort  A specific group of participants fulfilling certain criteria and generally treated at 
the same time . 
Electronic Data 
Capture (EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web -based applications, 
interactive voice response systems and clinical laboratory interfaces. EDC includes the use of Electronic Case Report Forms (eCRFs) which are used to 
capture data transcribed from paper source forms used at the point of care . 
End of the clinical 
trial The end of the clinical trial is defined as the last visit of the last participant or 
at a later point in time as defined by [CONTACT_760] . 
Enrollment  Point/time of participant entry into the study at which informed consent must 
be obtained .  
Estimand   A precise description of the treatment effect reflecting the clinical question posed by [CONTACT_6553]. It summarizes at a population- level what the 
outcomes would be in the same patients under different treatment conditions being compared. Attributes  of an estimand include the population, variable (or 
endpoint) and treatment of interest, as well as the specification of how the remaining intercurrent events are addressed and a population-level summary 
for the variable.  
Intercurrent events  Events occurring after treatment initiation that affect either the interpretation or 
the existence  of the measurements associated with the clinical question of 
interest.  
Investigational 
drug/ treatment  The drug whose properties are being tested in the study . 
Medication number  A unique identifier on the label of medication kits  
Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for 
randomization and who did not take study treatment, but have been 
inadvertently randomized into the study .  
Other treatment  Treatment that may be needed/allowed during the conduct of the study (i.e. 
concomitant or rescue therapy ). 
Participant  A trial participant (can be a healthy volunteer or a patient ). 
Participant number  A unique number assigned to each participant upon signing the informed consent. This number is the definitive, unique identifier for the participant and 
should be used to identify the participant throughout the study for all data 
collected, sample labels, etc. 
Personal data Participant information collected by [CONTACT_157058]. This data includes 
participant identifier information, study information and biological samples.  
Premature participant withdrawal  Point/time when the participant exits from the study prior to the planned completion of all study drug administration and/or assessments; at this time all 
study drug administration is discontinued and no further assessments are 
planned . 
Randomization 
number  A unique identifier assigned to each randomized participant . 
Screen Failure  A participant who did not meet one or more criteria that were required for 
participation in the study . 
[COMPANY_001]  Confidential  Page 9 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Source 
Data/Document  Source data refers to the initial record, document, or primary location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource . 
Start of the clinical 
trial The start of the clinical trial is defined as the signature [CONTACT_201698] [CONTACT_769355] . 
Study treatment  Any drug or combination of drugs  or intervention administered to the study 
participants as part of the required study procedures; includes investigational 
drug(s), control(s) or background therapy . 
Study treatment 
discontinuation When the participant permanently stops taking any of the study drug(s) prior 
to the defined study treatment completion date (if any) for any reason; may or 
may not also be the point/time of study discontinuation .  
Treatment 
arm/group  A treatment arm/group defines the dose and regimen or the combination, and 
may consist of 1 or more cohorts.  
Variable (or 
endpoint)  The variable (or endpoint) to be obtained for each participant that is required 
to address the clinical question.  The specification of the variable might include 
whether the participant experiences an intercurrent event.  
Withdrawal of 
study consent 
(WoC)  Withdrawal of consent from the study occurs only when a participant does not want to participate in the study any longer and does not allow any further 
collection of personal data .  
[COMPANY_001]  Confidential  Page 10 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Amendment 2 (20-Oct-2021)  
Amendment rationale 
The main purpose of this amendment is to reduce the sample size for this study.   
The initial sample size calculation for this open -label, one arm extension study was mainly 
based on the assumption that all eligible subjects completing the core study could be enrolled. 
Following the USM dated 27- May-2021, subjects requiring study treatment every 4 weeks will 
be discontinued, therefore , the originally planned number of subjects transitioning from the core 
study into the extension study will be reduced. Consequently, the sample size was re -assessed 
with the focus on the estimation of subjects who will be on a q20w interval. This estimation can be achieved with acceptable precision with a sample size of 250 . The study objectives will still 
be assessed with the revised sample size.  
In addition , information was included on the gender imbalance in the reported rates of 
intraocular inflammation -related adverse events following brolucizumab treatment.  
Changes to the protocol  
• Protocol summary: Aligned with amendment 2.  
• Section 3 Study design: Changed the number of participants to be enrolled from approximately 622 to 250. In addition, removed stipulation for minimum time interval 
between two injections  of 21 days as a 4 -week interval is no longer an option. 
• Section 4.5 Risk and benefits: Information added regarding the gender imbalance in the 
reported rates of intraocular inflammation -related adverse events following brolucizumab 
treatment. 
• Section 5 Study population: Changed the number of participants to be enrolled from approximately 622 at 190 sites to 250 at 60 sites.  
• Section 6.7.2 Instruction for prescribing and taking study treatment, and Section 10 Safety 
monitoring and reporting: For consistency, in the sentence “ If retinal vasculitis and/or 
retinal vascular occlusion is confirmed, subjects should be discontinued from study treatment. ”, replaced “should ” with “must”. 
• Section 9.1.2 Withdrawal of informed consent: Section was replaced with updated language based on latest protocol template. 
• Section 10 Safety monitoring and reporting: For consistency, incorporated the mandatory safety phone call required two weeks after the first injection (defined in Table 8 -2) in the 
consolidated list for safety monitoring.  
• Section 10.1.3 SAE reporting: Clarified the timing for SAE reporting to [COMPANY_001] as per latest protocol template.  
• Section 12.8  Sample size calculation : Section updated to implement the sample size  
reduction from 622 down to approximately 250 participants  expected to be enrolled into 
the extension study. 
• Minor editorial changes (e.g. typographical mistakes, grammatical changes, rewording) to improve flow and consistency have been made throughout the protocol. 
[COMPANY_001]  Confidential  Page 11 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this protocol amendment. 
 
[COMPANY_001]  Confidential  Page 12 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Summary of previous amendments  
Amendment 1 (13- Aug-2021) 
Amendment rational e 
The main reasons for the protocol amendment are: 
(1) To provide clarification and guidance on the early discontinuation of study treatment that is 
required for those subjects who are currently on q4w dosing beyond the first 3 monthly loading 
doses (“loading phase”)  or would need q4w dosing beyond the “loading phase” based on the 
investigator’s assessment. This is as per the urgent safety measure dated 27-May-2021 based 
on CTH258AUS04 (MERLIN) Year [ADDRESS_1176352] interpretable results (FIR) indicating a higher frequency of IOI including Retinal Vasculitis (RV), and Retinal Vascular Occlusion (RO) in brolucizumab 6 mg q4w when compared to aflibercept 2 mg q4w (IOI: 9.3% vs 4.5% of which RV: 0.8% vs 0.0%; RO: 2.0% vs 0.0%, respectively). 
(2) Additionally, as per the Urgent Safety Measure dated 10-August- 2021, the results of the 
mechanistic study BASICHR0049 identified a causal link with an immune -mediated 
mechanism of the previously identified risk of Retinal vasculitis (RV), and/or Retina l vascular 
occlusion (RO), typi[INVESTIGATOR_213719]. The protocol is hence amended to require 
discontinuation of study treatment in subjects who develop these events.  
(3) Finally, the safety sections were updated throughout the protocol including updating the 
Risks and Benefits section and creating a new section under Safety Monitoring to consolidate all the information regarding the risk mitigation into one section in the protocol. Additionally, as subjects treated with brolucizumab who experience intraocular inflammation may be at risk of developi[INVESTIGATOR_213722]/or retinal vascular occlusion they should be closely monitored and the investigator needs to evaluate the appropriateness of continuing further with study treatment when IOI only (without RV and/or RO) is present. 
Changes to the protocol  
Protocol sections changed in relation to urgent safety measures (USM) are: 
• Section 1.1 Background: Language was added to indicate that the interval between two 
brolucizumab doses should not be shorter than [ADDRESS_1176353] on the risk/benefit balance is considered to be low when patients are dosed ≥q8w after the loading phase. In sub-section “CRTH258A2303 study (TALON)”, c larified that, 
in the core study, the treatment intervals after the initiation phase with 3 monthly 
injections at Baseline, Week 4, and Week 8 will range from 8 weeks to 16  weeks, and that 
subjects requiring injections every 4 weeks after the loading phase will be discontinued from further study treatment. In addition, the results of the mechanistic study 
BASICHR0049 of blood samples from nAMD patients exposed to brolucizumab and having subsequently developed RV and/or RO were added. 
• Section 2.1 Primary estimands , and Table  2-1 Objectives and related endpoints : Text 
added to clarify analysis of 4 -week treatment intervals.  
[COMPANY_001]  Confidential  Page 13 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 • Section 3 Study design: Changes were made to clarify the minimal treatment interval and  
the requirement to discontinue from study treatment if subjects require treatment every 4 weeks beyond the loading phase. Reference to Section 9.1.1 added regarding early treatment discontinuation.  
• Figure 3-1 Study design: Updated the range for treatment intervals.  
• Section 4.1 Rationale for study design: Modified to clarify the shortest treatment interval  
• Section 4.2 Rationale for dose/regimen and duration of treatment: Language added to provide background of the USM. 
• Section 4.5 Risks and Benefits: Added the three  urgent safety measures related to adverse 
events observed in patients treated with brolucizumab from the MERLIN (CRTH258AUS04) study, the post marketing reports and the causal link  (results of the 
mechanistic study BASICHR0049).  
• Section 5.2 Exclusion criteria: Added criteria to exclude s ubject s who  require anti -VEGF 
IVT injections every 4 weeks. 
• Section 6.1.4 Treatment duration: Guidance added for subjects requiring injections every [ADDRESS_1176354] treatment to perform assessments for early treatment discontinuation.  
• Section [IP_ADDRESS] Permitted concomitant therapy requiring caution and/or action: Added guidance regarding SARS -CoV-[ADDRESS_1176355] 7 days before 
or after the administration of study treatment.  
• Section 6.7.2 Instruction for prescribing and taking study treatment: Changes were made to clarify the requirement to discontinue from study treatment if subjects require treatment every 4 weeks. Changes also made to update that if RV and/or RO is confirmed, subjects must be discontinued from study treatment. If only IOI (without RV and/or RO) is confirmed, the subject should be closely monitored and the investigator should evaluate the appropriateness of continuing further with study treatment.  
• Figure 6-1 Treatment regimen: Updated to update the range for treatment intervals. 
• Table 8 -1 Assessment schedule: Columns added for assessment visits after start of 
standard of care and for early treatment discontinuation visits, including respective footnotes. 
• Section 9.1.1 Study treatment discontinuation and study discontinuation: Clarification and instructions were added for subjects who discontinue from study treatment early.  
• Section 10 Safety monitoring and reporting: Consolidated the requirements for monitoring of adverse events of special interest that were already included in the previous version. Added the new requirement that if RV and/or RO is confirmed, subjects must be discontinued from study treatment. If only IOI (without RV and/or RO) is confirmed, the subject should be closely monitored and the investigator should evaluate the appropriateness of continuing further with study treatment.  
• Table 12-1 Primary and sensitivity  estimands: Clarification added regarding BCVA scores 
collected after start of standard of care. The estimands are re -ordered to match the order in 
the Table 2 -1. In addition, sensitivity estimands are added regarding the proportion of 
q12w. 
[COMPANY_001]  Confidential  Page 14 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 • Section 12.4.5 Sensitivity analyses for primary endpoint/estimand: Sensitivity analysis 
added regarding USM . Added MMRM abbreviation. 
Other changes incorporated in this amendment:  
• List of abbreviations: New abbreviations added in line with amendment 1. 
• Protocol summary: Aligned with amendment 1.  
• Section 2 Objectives and endpoints: Revised to make it clear that the baseline being referred to is that of the extension study and not the core study baseline. The prefix extension is added before the word  “baseline”. There are n o change s in the end-points or 
the primary analysis. The same prefix  ”extension” will be added for the CSFT and OCT 
end-points with no changes made to the analyses.  
• Section 6.3.1 Participant numbering: Updated section on participant numbering, because participant IDs in EDC may be different in IRT.  
• Section 6.7.2 Instruction for prescribing and taking study treatment. Changes made to 
update that if that if RV and/or RO is confirmed, subjects should be discontinued from study treatment. If only IOI (without RV and/or RO) is confirmed,  the investigator should evaluate the appropriateness of continuing further with study treatment. This has been updated in several sections. 
• Section 7 Informed consent procedures: Removed text to align with Investigator Brochure and ICF.  Section 8 Visit schedule and assessments: Clarification added for visit windows.  
• Table 8 -1 Assessment schedule and Table 8 -2 Safety assessments: Updated the visit 
window for mandatory safety phone call timing. The timing is changed from one week to two weeks and the window from +7 days to +14 days. Reason being that the median time of onset of AESI’s is about 21 days (as per [COMPANY_001] Pharmacovigila nce data) and 
therefore expanding the time frame may be more appropriate for pi[INVESTIGATOR_846220]’s. 
• Section 8.4 Safety: Added a reference for  monitoring, assessment and management of 
adverse events of inflammation, retinal vasculitis and/or retinal vascular occlusion . Also 
added imaging as key safety assessment. This change has been made in multiple sections 
of the protocol. 
• Section 10 Safety monitoring and reporting: Consolidated the requirements for monitoring 
of adverse events of special interest that were already included in the previous version. Added the new requirement that if that if RV and/or RO is confirmed, subjects should be discontinued from study treatment. If only IOI (without RV and/or RO) is confirmed, the subject should be closely monitored and the investigator should evaluate the appropriateness of continuing further with study treatment. 
• Section 10.1.3 SAE reporting: Clarified the timing for SAE reporting to [COMPANY_001] as per latest protocol template.  
• Section 10.1.4 Pregnancy reporting: Clarification added regarding follow-up during pregnancy and after childbirth. 
• Section 12.5.1 Correction of typographical error, and Section 12.5.2 Safety endpoints: Removed “by [CONTACT_3148]” because only one treatment arm in the study , and clarified that 
clinically relevant abnormalities in vital signs will be listed.  
• Section 12.8  Sample size calculation: Clarification regarding sample size analyses.  
[COMPANY_001]  Confidential  Page 15 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Protocol summary  
Protocol 
number  CRTH258A2303E1  
Full Title  A 56-week, phase IIIb/IV, open -label, one- arm extension study to assess the 
efficacy and safety of brolucizumab [ADDRESS_1176356] completed the 
CRTH258A2303 (TALON) study  
Brief title  An extension study assessing the efficacy and safety of brolucizumab in a Treat -
to-Control regimen in patients with neovascular age -related macular 
degeneration who have completed the CRTH258A2303 (TALON) study  
Sponsor and 
Clinical Phase  [COMPANY_001]  
Phase IIIb/IV  
Investigation 
type Drug  
Study type  Interventional  
Purpose and rationale  To evaluate the efficacy and safety of brolucizumab used in a Treat -to-Control 
regimen for treatment of patients with neovascular age-related macular 
degeneration with the objective to assess the potential for long durability up to 
20 weeks  
Primary 
Objective(s)  To evaluate the extended durability of brolucizumab in a Treat -to-Control 
regimen assessed as duration of the last interval with no disease activity up to 
Week 56. To evaluate the functional outcomes of brolucizumab in a Treat -to-
Control regimen assessed as average change of best corrected visual acuity 
from the extension baseline at week 52 and week 56  
Secondary 
Objectives  To evaluate the anatomical outcomes of brolucizumab in all patients and per randomized arm in the core study - assessed by [CONTACT_846229] -retinal fluid and/or sub- retinal fluid, and 
sub-retinal pi[INVESTIGATOR_846221], as seen by [CONTACT_846230] 52 and Week 56  
To assess the durability of brolucizumab in all patients and/or per randomized arm 
in the core study - measured as duration of last interval and maximum interval 
with no disease activity up to week 56, as well as change of the duration of last 
interval wit h no disease activity between extension baseline and Week [ADDRESS_1176357] corrected visual acuity from extension 
baseline to week 52 and week 56  
To assess the safety of brolucizumab – measured as occurrence of ocular and 
non-ocular adverse events up to week [ADDRESS_1176358] completed the CRTH258A2303 
(TALON) study  are expected to be enrolled in approximately 60 sites worldwide  
[COMPANY_001]  Confidential  Page 16 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Key Inclusion criteria  • Signed informed consent must be obtained prior to participation in the study  
• The participant has successfully completed the TALON core study at the 
week 64 visit (End of Study)  
Key Exclusion criteria  • Participant has a medical condition or personal circumstance which precludes study participation or compliance with study procedures, as 
assessed by [CONTACT_737]  
• Participant has discontinued study treatment in the core study  
• Anti-VEGF treatment is futile in the study eye, in the investigator's opi[INVESTIGATOR_1649]  
• Pregnant or nursing (lactating) women, where pregnancy is defined as the 
state of a female after conception and until the termination of gestation, 
confirmed by a positive human chorionic gonadotropin (hCG) pregnancy test  
Study 
treatment  Brolucizumab 6 mg/0.05 mL 
Efficacy 
assessments • Best corrected visual acuity using ETDRS -like charts  
• Spectral Domain Optical Coherence Tomography  
• Color Fundus Photography  
Key safety assessments • Monitoring of adverse events 
• Ophthalmic examinations and imaging  
• Vital signs (pulse and blood pressure)  
• Pregnancy testing  
Other 
assessments  Ocular Coherence Tomography Angiography  
Data analysis The primary analyses will be conducted in the full analyses set with missing data imputed based on the last observation carried forward method. 
Duration of the last interval with no disease activity up to Week 56 will be 
estimated using proportions with two- sided 95% Binomial Confidence Intervals 
and simultaneous Confidence Intervals obtained based on Goodman method 
(1965). The  change in best corrected visual acuity from extension baseline at 
Week [ADDRESS_1176359] corrected visual acuity will be accompanied by [CONTACT_1192]- sided 95% 
Confidence Intervals.   
Additional analysis is planned to evaluate the impact of the COVID -19 pandemic 
and the q4w urgent safety measures on the primary and selected secondary 
endpoints . 
Key words  Neovascular age- related macular degeneration, anti -VEGF, choroidal 
neovascularization, individualized treatment  
[COMPANY_001]  Confidential  Page 17 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 1 Introduction  
1.1 Background 
Age-related macular degeneration (AMD) is a leading cause of severe vision loss in people, 
affecting 11.6% to 18.5% of individuals between 60 and 69 years old and 31.6% to 45.3% of individuals between 80 and 84 years old in North America, Europe, and Oceania (Wong et  al 2014). Genetic, environmental and health factors play an important role in the 
pathogenesis of the disease.  
AMD is classified into 2 clinical subtypes: the non -neovascular (atrophic) or dry form, and the 
neovascular (exudative) or wet form ( Ferris  et al 1984, Lim et al 2012, Miller  2013). 
Neovascular AMD (nAMD) is characterized by [CONTACT_258403] (neovascularization) under the retinal pi[INVESTIGATOR_1836] (RPE) or sub- retinal space from the 
subjacent choroid, termed choroidal neovascularization (CNV) ( Ferris  et al 1984). These newly 
formed vessels have an increased likelihood to leak blood and serum, damaging the retina by [CONTACT_286819]. This damage to the retina results in progressive, severe, and irreversible vision loss ( Shah  and Del  Priore  2007, 
Shah  and Del  Priore  2009). Without treatment, most affected eyes will have poor central vision 
(20/200) within 12 months ( Blinder et al 2003 ). Although the neovascular form of the disease 
is only present in about 10 % of all AMD cases, it accounted for approximately 90 % of the severe vision loss from AMD prior to the introduction of antivascular endothelial growth factor (anti-VEGF) treatments ( Ferris  1983 ). 
Anti -VEGF in nAMD  
Vascular endothelial growth factor (VEGF) has been shown to be elevated in patients with nAMD and is thought to play a key role in the neovascularization process ( Spi[INVESTIGATOR_846222] 2000).  
The use of intravitreal injection (IVT) pharmacotherapy targeting VEGF has significantly improved visual outcomes in patients with nAMD ( Bloch  et al 2012, Campbell et al 2012). 
Intravitreal administration of anti- VEGF treatments is the current standard of care in nAMD.  
Treat -and- Extend treatment regimen  
Typi[INVESTIGATOR_897], a Treat -and- Extend (T&E) treatment regimen includes a loading phase of monthly 
injections, followed by a maintenance phase during which the injection interval is progressively prolonged if there is no disease activity (DA), primarily determined by [CONTACT_7349] (OCT) and visual acuity assessment, or shortened if disease recurs. The T&E treatment regimen aims at identifying optimal individual injectio n intervals to minimize the 
number of injections and reduce visit burden while maintaining the vision gains obtained at the end of the loading phase during the maintenance phase. T&E treatment regimen has been approved in the labels of anti -VEGF treatments , such as ranibizumab (Lucentis
®) and 
aflibercept (Eylea®) in Europe and many other countries. The treatment paradigm has come in 
a variety of regimens.  
Whereas most T&E regimens entail extending or shortening the injection interval based on absence or presence of DA, the Treat -to-Control (TtC) regimen emphasizes sustained disease 
control to determine the optimal treatment interval for each patient rather than solely adjusting treatment intervals. For instance, it allows patients that may not benefit from treatment interval 
[COMPANY_001]  Confidential  Page 18 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 extension to be temporarily or lastingly maintained on a treatment interval. While T&E regimens have been associated with a reduction in treatment and visit burdens in AMD, the number of visits remain relatively high for most patients as the average number of injections in 
Lucentis
® and Eylea® studies range from [ADDRESS_1176360] 2 years ( Wykoff et  al 2015, DeCroos  et al 2017, Wykoff et  al 2017 , 
Guymer et  al 2018, Silva  et al 2018, Gillies  et al 2019, Kertes  et al 2019, Ohji et al 2020).  
There still is a need for highly effective treatments that prolong intervals between injections and further reduce treatment burden, while maintaining vision gains. 
Brolucizumab 
Brolucizumab (RTH258, ESBA1008, AL -[ZIP_CODE]), is a humanized single -chain antibody 
fragment (scFv) with a molecular weight of ~26 kilodalton (kDa) which inhibits VEGF -A 
binding to its receptors VEGFR1 and VEGFR2. Brolucizumab is administered by [CONTACT_846231] [ADDRESS_1176361] 2019 and 
many other countries (e.g. EU countries, Australia, Japan and Canada) subsequently, for the treatment of nAMD.  
The efficacy and safety of brolucizumab in subjects with nAMD has been demonstrated in two Phase III pi[INVESTIGATOR_36491] (RTH258 -C001 [HAWK] and RTH258- C002 [HARRIER]). nAMD 
patients received brolucizumab every 12 weeks (q12w), with the option of adjusting to a q8w dosing interval based on DA, or aflibercept q8w, after three monthly loading doses. Brolucizumab was non- inferior to aflibercept with regards to change from Baseline in BCVA 
at week 48, with over half of the participants in the brolucizumab 6 mg arm maintained exclusively on the q12w dosing interval (56% in HAWK and 51% in HARRIER). Significantly fewer patients in the brolucizumab 6 mg arm had DA at Week 16 in a head -to-head comparison 
based on a matching dosing intervals, with a relative decrease of 30% (P = 0.0022) versus aflibercept. Significantly fewer patients on brolucizumab had intraretinal fluid (IRF) and/or subretinal fluid (SRF), with a 35% and 33% reduction relative to aflibercept at Week 16 (P < 0.001 for both) in HAWK and HARRIER, respectively, and a 31% and 41% reduction relative to aflibercept at Week 48 in HAWK and HARRIER, respectively (P < 0.0001 for both). These advantages for brolucizumab were maintained in the second year. Safety was comparable between the treatment arms over [ADDRESS_1176362] marketing authorization approval in October 2019 for the treatment of nAMD, adverse events of retinal vasculitis and/or retinal vascular occlusion, that may result in severe vision loss and typi[INVESTIGATOR_213713], have been reported from post-marketing experience with brolucizumab (Beovu
®).  
Results of the mechanistic study BASICHR0049 of blood samples from nAMD patients exposed to brolucizumab and having subsequently developed Retinal Vasculitis (RV) and/or Retinal Vascular Occlusion (RO), taken together with accumulated data of the association of 
treatment- emergent immunogenicity and intraocular inflammation (IOI) indicate a causal link 
between the treatment- emergent immune reaction against brolucizumab and the  brolucizumab-
related “retinal vasculitis and/or retinal vascular occlusion, typi[INVESTIGATOR_213719]”.  
This finding supports the  requirement to discontinue treatment with brolucizumab in patients 
who develop events of RV and/or RO. 
[COMPANY_001]  Confidential  Page 19 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 In addition, based on the USM (CRTH258AUS04 first interpretable results [FIR]), the interval between two brolucizumab doses should not be shorter than 8 weeks beyond the loading phase.  
These impacts on the risk /benefit balance of the product are considered to be low and the overall 
risk/benefit assessment remains positive, when patients are dosed  at q8w or longer  after the 
loading phase and when patients who develop RV and/or RO are discontinued from further 
treatment with brolucizumab . 
For further details, please refer to the investigator brochure (IB) or package insert whichever is applicable. 
CRTH258A2303 study (TALON)  
There is an ongoing study CRTH258A2303 (TALON) which intends to complement the current 
clinical dataset on brolucizumab by [CONTACT_846232] T&E concept prevalent in the current management of patients with nAMD. It will be comparing the efficacy 
and safety of brolucizumab and aflibercept administered  in three monthly injections at Baseline, 
Week 4, and Week 8  (loading phase) , followed by [CONTACT_846233] 4 -week -adjustment Treat -to-
Control regimen with treatment intervals from 8 to 16 weeks. S ubjects requiring injections 
every 4 weeks afte r the loading phase will be discontinued from further study treatment. 
This study, CRTH258A2303E1, is an extension study of the CRTH258A2303 (TALON) study, aiming at gathering additional long -term efficacy and safety evidence about brolucizumab in a 
TtC treatment regimen with treatment intervals further extended up to 20 week s in nAMD. It 
intends to contribute to the growing clinical dataset of brolucizumab by [CONTACT_846234], efficacy, and durability in nAMD. 
1.2 Purpose 
The purpose of this study is to evaluate the efficacy and safety of brolucizumab used in a Treat -
to-Control (TtC) regimen with maximum treatment intervals up to 20 weeks for the treatment 
of patients with neovascular age -related macular degeneration (nAMD)  who have completed 
the CRTH258A2303 study (TALON). 
In addition, switch data from aflibercept to brolucizumab is collected.  
2 Objectives and endpoints  
Table 2-1 Objectives and related endpoints 
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
• To evaluate the extended durability of 
brolucizumab in a TtC regimen with respect 
to the duration of treatment intervals at 
Week 56  • Duration of the last interval with no DA up to 
Week 56  
• To evaluate the functional outcomes of 
brolucizumab in a TtC regimen with respect • Change in BCVA from extension baseline at 
Week 52 and Week 56  
[COMPANY_001]  Confidential  Page 20 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Objective(s)  Endpoint(s)  
to average change in BCVA at Week 52 and 
Week 56  
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
• To evaluate the anatomical outcomes of brolucizumab in all patients and per randomized arm in the core study
 • Change in CSFT from extension baseline to 
Week 52 and Week 56  
Number of visits with presence of IRF and/or SRF, and sub -RPE fluid in the central 
subfield, as assessed by [CONTACT_66309] -OCT at Week 
52 and Week 56  
• To assess the durability of brolucizumab in 
all patients and/or per randomized arm in 
the core study  • Duration of the last interval with no DA up to 
Week [ADDRESS_1176363] interval with no DA between extension baseline and 
Week 56   
• To assess the functional outcomes of brolucizumab per randomized arm in the 
core study   • Change in BCVA  from extension baseline to 
Week 52 and Week 56  
• To assess the safety of brolucizumab  • Occurrence of Ocular and Non -ocular AEs 
up to Week [ADDRESS_1176364]: 1. what is the effect of brolucizumab 6 mg on treatment interval extension? and 2. what is the effect of brolucizumab [ADDRESS_1176365] completed the CRTH258A2303 study? 
These two effects were targeted to estimate the effect of brolucizumab in a TtC regimen with 
maximum treatment intervals up to 20 weeks without breaking masking of the CRTH258A2303 study (TALON).  
The primary estimand is described by [CONTACT_6570]:  
1. Population: participants who have completed the CRTH258A2303 study (TALON) irrespective of the study treatment received in the core study. Further details about the population are provided in Section  5. 

[COMPANY_001]  Confidential  Page 21 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 2. The co- primary variable [ADDRESS_1176366] interval with no DA up to Week 56, i.e. the 
proportion of participants in q4w, q8w, q12w, q16w and q20w intervals (interval distribution) at last interval with no DA up  to Week 56 (s ubjects who will be assigned to a 4- week interval 
will be analyzed as such, but discontinued from fur ther study treatment). 
3. Treatment of interest: brolucizumab 6 mg will be taken for the entire study duration. Further details about the investigational drug are provided in Section  6. 
Handling of remaining intercurrent events:  
• Study treatment discontinuation: For the co -primary endpoint of change in BCVA, a 
hypothetical treatment strategy will be applied to estimate the treatment effect under the hypothetical assumption that the patient would not start an alternative anti- VEGF 
treatment (i.e. standard of care therapy) on the study eye. For the co- primary endpoint of 
duration of treatment interval, a ‘while on treatment strategy’ will be applied  as disease 
stability assessment will not be performed after the patient discontinued treatment.  
• Study treatment interruption: For both the co -primary endpoints, a treatment policy 
strategy will be applied. 
The summary measure for the co -primary variable [ADDRESS_1176367] 
completed the CRTH258A2303 study (TALON). 
Participants who consent and meet all the inclusion and none of the exclusion criteria will be 
enrolled into this extension study and receive brolucizumab [ADDRESS_1176368]- treatment follow -up. 
There will be two periods in this study, see Figure 3-1: 
• Treat -to-Control treatment period: from Baseline (Day 1) to Week 52  
• Post-treatment follow -up period: from Week 52 to Week 56.  
[COMPANY_001]  Confidential  Page 22 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Figure 3-1 Study design 
 
Depending on visit schedules:  
* 62 weeks (core) / 54 weeks (extension) ** Week 62 (core) / Week 54 (extension)  
Baseline visit: Day 1  
Participants should sign informed consent no later than the Week 64 (EOS) visit of the core study. Baseline visit for the extension study (extension baseline) should occur on the same day as the Week 64  (EOS)  visit of the core study . Participants will be assessed on inclusion and 
exclusion criteria of the extension study at the baseline visit.  
The study eye will be the same eye that received brolucizumab or aflibercept treatment in the core study. 
Treat -to-Control treatment period: Day 1 to Week 52 
All efforts should be made to adhere to the study visit schedule within a ±14day window 
(baseline visit should occur on the same day as the Week 64  (EOS)  visit of the core study).  For 
a given study visit, assessments can be performed on [ADDRESS_1176369] injection visit of the core study. The treatment interval can then be extended by 4 weeks at a time based on the investigator’s judgment of visual and/or anatomic outcomes, as per guidance provided, for example, no change in visual acuity and in other signs of the disease (e.g. IRF, SRF, hemorrhage, leakage, etc.). Patients who have  the last 
injection interval with no D A of q16w in the core study should be injected at another q16w  

[COMPANY_001]  Confidential  Page 23 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 interval before start to extend intervals in the extension study.  The maximal treatment interval 
is 20 weeks.  
The injection interval can also be maintained if the investigator deems that the patient will not 
benefit from injection interval extension.  
The interval should be shortened by 4 weeks at a time if DA recurs (to a minimal interval of 8 
weeks).  
The investigators have options to plan for an inspection visit when the treatment intervals are extended. Further details are provided in Section  6.7.2. 
For all participants, the last potential study treatment will be at the Week [ADDRESS_1176370]-treatment follow -up period: Week 52 to Week 56 
For all participants completing the study, the EOS (Week 56 ±21 days) assessment s will be 
performed [ADDRESS_1176371] treatment administration (Week 52/54).  
Participants withdrawn from the study prior to study completion within less than [ADDRESS_1176372] study treatment will be asked to return for an EOS visit, 4 weeks (±14 days) following 
their last study treatment administration (EOT).  For early treatment discontinuations (ETD) 
refer to Section 9.1.1. 
[ADDRESS_1176373] completed the CRTH258A2303 (TALON) study, which compar ed the efficacy and safety 
of brolucizumab and aflibercept administered in the same TtC regimen with the treatment intervals from [ADDRESS_1176374] treatment interval in the CRTH258A2303 (TALON) study, i.e. q8w, q12w and q16w, with an additional treatment 
interval of 20 weeks added in the extension study. 
Co-primary efficacy endpoints based on treatment interval and BCVA were chosen to evaluate 
the benefits of treatment in terms of treatment durability and functional outcome, respectively:  Treatment intervals may be extended, reduced, or maintained, based on the evaluation of DA 
by [CONTACT_431]. The distribution of the last interval with no DA up to Week [ADDRESS_1176375] in terval will be shortened by 4 
weeks down to a minimum of 8 weeks.  
The co -primary efficacy endpoint based on BCVA (ETDRS letters) will also be assessed. 
Historically, the change from baseline in BCVA at a selected time point is considered appropriate as the primary efficacy endpoint in confirmatory nAMD studies, based on the 
[COMPANY_001]  Confidential  Page 24 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 evidence available from existing anti -VEGF treatments in nAMD (e.g. ranibizumab, 
aflibercept).  
The co -primary endpoint will be assessed as average change from the extension baseline in 
BCVA at Week [ADDRESS_1176376] BCVA gain and could introduce a bias on BCVA gain if measured at a single fixed assessm ent time point. Averaging change in BCVA from 
baseline at two time points 4 weeks apart will mitigate this potential bias.  
Approximately 52 weeks of treatment in a TtC regimen, allows up to two consecutive q20w intervals and the evaluation of the long- term safety and efficacy of brolucizumab.  
4.2 Rationale for dose/regimen and duration of treatment  
The dose and regimen for brolucizumab is based on the following considerations: 
• Brolucizumab is well tolerated at a dose of 6 mg administered three times every four 
weeks during the loading phase, based on the previous clinical Phase III program in which 
1088 participants with nAMD received brolucizumab (RTH258-C001 - HAWK and 
RTH258 -C002 - HARRIER). The nAMD study results regarding q12w/q8w maintenance 
dosing interval support stretching the interval between injections during the TtC phase to reduce the treatment burden (see Section  1.1).  
• In a recent Treat and Extend study, treatment intervals were extended to the maximum interval of 16 weeks as early as Week 40 for some Japanese patients with nAMD treated with aflibercept 2 mg in a Treat -and- Extend regimen where treatment intervals could b e 
every 4-week adjusted based on DA, following 3 consecutive 4- week injections and a 8-
week injection ( Ohji et al 2020).  One could expect that patients could also be effectively 
and safely injected with brolucizumab 6 mg at 16- week intervals, as brolucizumab 6 mg 
dosed q12w/q8w was superior to aflibercept 2 mg dosed q8w in terms of fluid control and suppression of DA as seen in RTH258-C001 - HAWK and RTH258 -C002 - HARRIER. 
Hence, the treatment interval range in the ongoing CRTH258A2303 (TALON) study is from 4 to 16 weeks for brolucizumab and aflibercept. 
• Evidence from ranibizumab study in nAMD (CRFB002A2413 – SUSTAIN) showed that 20.5% of patients did not receive any additional dose during a PRN phase (re- treatment 
criteria were guided by [CONTACT_846235]) for periods lasting up to eight months. It indicates that some patients may not need frequent injections. These patients may benefit from brolucizumab 6 mg administered at 20 -week intervals as in the current study. 
• CRTH258AUS04 (MERLIN) is a two -year, multicenter, randomized, double masked, 
Phase III a study evaluating brolucizumab 6 mg q4w versus aflibercept 2 mg q4w in 
patients with nAMD with persistent fluid.  Review of the 52-week FIR led to an urgent 
safety communication based on an increased incidence of IOI and related adverse events including retinal vasculitis (RV), and retinal vascular occlusion (RO) in patients with q4w dosing with brolucizumab beyond the “loading phase”. IOI including RV, and RO were reported at a higher frequency in brolucizumab 6 mg q4w when compared to aflibercept 2 mg q4w (IOI: 9.3% vs 4.5% of which RV: 0.8% vs 0.0%; RO: 2.0% vs 0.0%, 
[COMPANY_001]  Confidential  Page 25 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 respectively ). Accordingly, the protocol was  amended to discontinue subjects from study 
treatment who require treatment every 4 weeks during the extension study. 
• The route of administration is an intravitreal injection as for all anti -VEGF treatments 
currently approved for the treatment of nAMD. 
• Study duration of 56 weeks allows two consecutive 20- week intervals to assess long -term 
efficacy and safety of brolucizumab in a TtC regimen.  
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs  
Not applicable 
4.4 Purpose and timing of interim analyses/design adaptations  
Not applicable 
4.5 Risks and benefits  
The risk to participants in this trial may be minimized by [CONTACT_30786], as well as close clinical monitoring described  in Section  6.7.2, 
Section  8.4 and Section  10. 
Adverse events (AEs) of retinal vasculitis and/or retinal vascular occlusion  have occurred since 
the Oct -2019 marketing authorization approval for brolucizumab ( Beovu®) in the treatment of 
nAMD.  These AEs may result in severe vision loss and typi[INVESTIGATOR_846223]. Based on clinical studies, IOI related adverse events, including retinal vasculitis 
and retinal vascular occlusion, were reported more frequently in female patients treated with brolucizumab than male patients (e.g.  5.3% females vs. 3.2% males in HAWK and HARRIER ). 
Results of the mechanistic study BASICHR0049 of blood samples from nAMD patients exposed to brolucizumab and having subsequently developed Retinal Vasculitis (RV) and/or Retinal Vascular Occlusion (RO), taken together with accumulated data of the association of 
treatment- emergent immunogenicity and intraocular inflammation (IOI) , indicate a causal link 
between the treatment- emergent immune reaction against brolucizumab and the  brolucizumab-
related “retinal vasculitis and/or retinal vascular occlusion, typi[INVESTIGATOR_213719]”. 
This finding supports the  requirement to discontinue treatment with brolucizumab in patients 
who develop events of RV and/or RO. 
In addition, based  on USM (CRTH258AUS04 FIR) , the brolucizumab dos ing interval should 
not be less  than [ADDRESS_1176377] adhere to the contraception requirements outlined in the exclusion criteria. If there is any question that the participant will not reliably comply, they should not be entered or continue in the study. 
In both Phase III studies (HAWK, HARRIER) in nAMD, brolucizumab demonstrated non-
inferiority to aflibercept in mean change in BCVA from baseline to Week 48. These results 
[COMPANY_001]  Confidential  Page 26 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 were achieved while a majority of participants on brolucizumab 6 mg – 56% in HAWK and 
51% in HARRIER – were maintained on a q12w dosing interval following the loading phase 
through Week 48, i.e., with a reduced treatment frequency compared to aflibercept. 
Brolucizumab safety was comparable to aflibercept, with the overall incidence of adverse events balanced across all treatment groups in both studies.  
[ADDRESS_1176378] completed the CRTH258A2303 study (TALON) with the EOS visit at Week [ADDRESS_1176379] meet all of the following criteria:  
1. Signed informed consent must be obtained prior to participation in the study.  
2. The participant has successfully completed the TALON core study, as defined by [CONTACT_846236] 64 visit (EOS) of the core study.  
5.2 Exclusion criteria 
Patients fulfilling any of the following criteria at study entry are not eligible for inclusion in this study. No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study population will be representative of all eligible patients.  
1. Participant has a medical condition or personal circumstance which precludes study participation or compliance with study procedures, as assessed by [CONTACT_737].  
2. Participant has discontinued study treatment in the core study. 
3. Anti-VEGF treatment is futile in the study eye, in the investigator's opi[INVESTIGATOR_1649]. 4. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female 
after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) pregnancy test. 
5. Women of child- bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using highly effective methods of contraception during the 
study drug administration and for 3 months after stoppi[INVESTIGATOR_846224]. 
Highly effective contraception methods include:  
[COMPANY_001]  Confidential  Page 27 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 • Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_104]. 
• Male sterilization (at least 6 months prior to baseline). For female participants on the study, the vasectomized male partner should be the sole partner for that participant. 
• Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate  < 
1%), for example hormone vaginal ring or transdermal hormone contraception. 
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a minimum of [ADDRESS_1176380] had 12 months of natural (spontaneous) 
amenorrhea with an appropriate clinical profile (e.g. age , appropriate history of vasomotor 
symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_109017]- bearing potential. If local 
regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form. 
6. Subject requires  study treatment every 4 weeks. 
6 Treatment 
6.1 Study treatment  
6.1.1 Investigational and control drugs 
Table 6-1 Investigational drug 
Investigational 
Drug  
(Name [CONTACT_6673])  Pharmaceutical 
Dosage Form  Route of 
Administration  Supply Type  Sponsor (global 
or local)  
Brolucizumab 
6 mg (RTH258 
6 mg/0.05 mL)  Solution for 
injection  Intravitreal use Prefilled syringes / Glass vials  Global  
 
Brolucizumab will be provided in a single use, sterile glass vial, or may be provided in prefilled 
syringe ( in selected countries) , containing sufficient brolucizumab to deliver a 6 mg dose when 
administering a volume of 0.05 mL. 
[COMPANY_001]  Confidential  Page 28 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 [COMPANY_001] will ensure sufficient supplies of brolucizumab for treatment use to allow for completion of the study. 
6.1.2 Additional study treatments 
No other treatment beyond investigational drug is included in this trial. 6.1.3 Treatment arms/group 
All eligible participants will receive brolucizumab 6 mg TtC treatment from baseline to Week 
52. 
6.1.4 Treatment duration 
The planned duration of treatment is 52 weeks ([ADDRESS_1176381] 
received study treatment at an odd number of inspection visits). Discontinuation of study treatment for a participant occurs when study drug is stopped earlier than the protocol planned  
duration and can be initiated by [CONTACT_6633].  
Study treatment will also be discontinued for patients who require injections every 4 weeks.  
If retinal vasculitis, and/or retinal vascular occlusion is confirmed, subjects must be 
discontinued from study treatment.  
Subjects who prematurely discontinue study treatment for any reason, except for withdrawal of 
consent, should continue in the study. Subjects should return [ADDRESS_1176382] study treatment to perform the assessments for early treatment discontinuation (E TD).  
6.2 Other treatment(s)  
6.2.[ADDRESS_1176383] the participant to notify the study site about any new medications the participant takes after enrollment in the study. All medications, procedures, and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy and blood tra nsfusions) administered after the 
participant was enrolled into the study must be recorded on the appropriate eCRF. 
Concomitant medications which are ongoing at the time of the Week 64 (EOS) visit in the core 
study must be recorded, and entries in the extension study database should match those in the core study database as appropriate.  
Each concomitant drug must be individually assessed against the prohibited medication Table  6-2. If in doubt, the investigator should contact [CONTACT_846237] a participant or allowing a new medication to be started. If the participant is already enrolled, contact [CONTACT_846238]. 
[IP_ADDRESS] Permitted concomitant therapy requiring caution and/or action  
Fellow eyes  
[COMPANY_001]  Confidential  Page 29 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 During the study, standard of care or other treatments according to the investigator's practice for nAMD and other diseases in the fellow eye are permitted at any time and must be recorded in the appropriate eCRF page. Treatment of the fellow eye must be scheduled in a way not to disturb the schedule for visits and treatments in the study eye. The fellow eye must be monitored according to routine practice and adverse events (AEs) captured in the eCRF.   
Study eyes  
Administration of topi[INVESTIGATOR_846225]. Corticosteroids administered via intra -nasal, inhaled, intra -articular or non -extensive dermal 
route (< 20% total body surface area) are also permitted during th e study. For other routes of 
corticosteroid administration, refer to Section  6.2.2. 
If cataract surgery is necessary, attempt to schedule cataract surgery ≥ [ADDRESS_1176384] recent study treatment. Study treatment may be resumed ≥ [ADDRESS_1176385] surgery, assuming an absence of surgically -related complications.  
If yttrium aluminum garnet (YAG) laser is necessary, it should be performed ≥ [ADDRESS_1176386] study treatment at the Baseline visit.  
6.2.2 Prohibited medication 
Use of the treatments displayed in the below table are not allowed from the Week 64 (EOS) 
visit of the core study.  
Table 6-2 Prohibited medications and procedures 
Medication  Prohibition period  Action taken  
Study Eye      
Any periocular injection 
or intraocular administration 
of corticosteroids  
(except if needed as a short -
term treatment of AE)   Anytime  Discontinue study treatment  (except if for 
treatment of AE)  
Anti-VEGF therapy other 
than assigned study medication   Anytime  Discontinue study treatment  
Panretinal laser, PDT laser, or focal laser 
photocoagulation with 
involvement of the 
macular  area Anytime  Discontinue study treatment  
Any investigational 
drug,  biologic or device  Anytime  Discontinue study treatment  
Systemic      
Anti-VEGF treatment  Anytime  Discontinue study treatment  
[COMPANY_001]  Confidential  Page 30 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Medication  Prohibition period  Action taken  
Any investigational 
drug,  biologic or device  Anytime  Discontinue study treatment  
Medications known to be toxic to the lens, retina or optic 
nerve, including ethambutol, 
chloroquine/hydroxychloroquine, deferoxamine, 
phenothiazines and tamoxifen (except temporary use for 
COVID -19 treatment)  Anytime  Discontinue study treatment  
Fellow eye      
investigational drug, biological, 
device  Anytime  None 
 
6.2.[ADDRESS_1176387] of the 
participant to receive prohibited treatment (Section  6.2.2) in the study eye, the investigator 
should follow the instructions for study treatment discontinuation or study discontinuation provided in Section  9.1. 
6.[ADDRESS_1176388] Number (Subject No.) that is assigned when the subject is first enrolled for screening and is retained as the primary identifier for the subject throughout his/her entire participation in the trial. The Subject No. consists of the Center Number (4 digit number for Center No. as assigned by [CONTACT_5359]) with a sequential subject number suffixed to it ([ADDRESS_1176389] No.), so that each subject is numbered uniquely across the entire database. Upon signing the informed consent form, the subject is assigned to the next sequential Subject No. available in the electronic data capture (EDC) system.  
6.3.2 Treatment assignment, randomization  
All participants will be treated with brolucizumab, no randomization will be performed in this study.  
IRT will be used to assign kit numbers for each treatment occasion, in order to manage study 
drug supply at site level. 
6.4 Treatment blinding  
Treatment will be open to participants, investigators/site personnel, sponsor clinical trial team (CTT) and monitors while randomization data from the core study will be kept strictly 
[COMPANY_001]  Confidential  Page 31 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 confidential for participants, investigators/site personnel, sponsor CTT and monitors until database lock. 
Should there be a reasonable need to unmask the core study treatment before the database lock 
of this extension study, investigator shall contact [CONTACT_5343].  
6.5 Dose escalation and dose modification  
Investigational treatment dose adjustment is not permitted.  Interruption of study treatment is 
allowed if warranted by [CONTACT_1149]. 
6.6 Additional treatment guidance  
6.6.1 Treatment compliance 
IRT needs to be accessed by [CONTACT_846239]. Registration of all visits in the IRT system is necessary and when treatment is warranted, IRT will provide a medication (kit) number to administer the investigational product to the participant. The date and time of all study treatment injections administered during the study and any deviations from the protocol treatment schedule will be captured by [CONTACT_846240]. 
Exposure to the study treatment will be based on the number of injections administered. 
Compliance with the study treatment will be assessed by [CONTACT_846241]. 
6.7 Preparation and dispensation  
Each study site will be supplied with study drug in packaging as described under investigational drugs Section  6.1. A unique medication number is printed on the study medication label. 
Investigator staff will identify the study medication kits to dispense to the participant by [CONTACT_105245](s). The study medication has a 2- part 
label (base plus tear -off label), immediately before dispensing the medication kit to the 
participant, site personnel will detach the outer part of the label from the packaging and affix it to the source document. 
6.7.1 Handling of study treatment and additional treatment  
[IP_ADDRESS] Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, all study treatment mus t be registered in the IRT 
system and stored according to the instructions specified  on the labels  and in the Investigator’s 
Brochure. 
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints 
are to be reported to the respective [COMPANY_001]  CO Quality Assurance.  
[COMPANY_001]  Confidential  Page 32 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Medication labels will be in the local language and comply with the legal requirements of each country. They will include storage conditions for the study treatment but no information about the participant except for the medication number . 
The investigator/site personnel must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_30798].  
At the conclusion of the study, and as appropriate during the course of the study, the 
investigator/site personnel will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the [COMPANY_001]  monitor o r to the [COMPANY_001]  address 
provided in the investigator folder at each site. 
6.7.2 Instruction for prescribing and taking study treatment  
There will be only one treatment phase in the extension study which is similar to the TtC phase 
of the core study and is defined as follows: 
Figure 6-1 Treatment regimen 
 
 
#The treatment interval can also be maintained if the investigator deems that the patient will 
not benefit from treatment interval extension  
*week 54, depending on visit schedule 
Treat -to-Control treatment phase (Baseline/Day 1 to Week 52):  
Treatment intervals will be either [ADDRESS_1176390] 
be discontinued from further study treatment if treatment is required every 4 weeks.  

[COMPANY_001]  Confidential  Page 33 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 The participant will receive the first injection based on the next planned injection interval decided by [CONTACT_846242]. For example, if a participant has the last injection visit at Week [ADDRESS_1176391] injection visit for this participant will be planned at Week 8 of the extension study (12 weeks from Week 60 of the core study).  
At each injection visit, DA should be assessed using anatomic and functional outcomes (e.g. 
SD-OCT, BCVA, etc.). Based on investigator’s judgment of visual and/or anatomic outcomes, 
the treatment interval can be further extended by 4 weeks at a time, if th ere is no DA, i.e. no 
change in visual acuity and in other signs of the disease (e.g. IRF, SRF, hemorrhage, leakage, etc.).  
Participants whose last injection interval in the core study is q16w and are without DA should be injected at another q16w interval  in the extension study before extending to q20w in the 
extension study.  
The treatment interval can also be maintained if the investigator deems the participant will not 
benefit from treatment interval extension.  
If DA recurs, the interval should be shortened accordingly by 4 weeks at a time, to a minimal interval of 8 weeks.  
When the investigator decides to extend the treatment interval from 16 to 20 weeks, the investigator has the option to plan for an inspection visit  4 weeks before the next treatment visit 
(i.e. [ADDRESS_1176392] treatment visit) to assess DA. If the study eye has no DA at the inspection visit, the participant will not receive study treatment at the inspection visit but 4 weeks later. If the investigator observes DA in the study eye at the inspection visit, the participant will receive study treatment at this visit. The treatment interval will then be reduced 
by 4 weeks and the next study treatment visit will be planned 12 weeks after the inspection visit.   
When the investigator decides to extend the treatment interval from 8 to 12 weeks, the 
investigator has the option to plan for an inspection visit 2 weeks before the next treatment visit (i.e. [ADDRESS_1176393] treatment visit) to assess DA. If the study eye has no DA at the 
inspection visit, the participant will not receive study treatment at the inspection visit but [ADDRESS_1176394] a study visit 
[COMPANY_001]  Confidential  Page 34 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 at Week 54; for these participants, the Week [ADDRESS_1176395] in lieu of the visit at Week 52 (unless this visit is inspection visit), respectively . 
The last potential study treatment may be administered at the Week 52 visit (or at the Week [ADDRESS_1176396] received study treatment at an odd number of inspection visits).  
DA assessments will be recorded in the IRT system by [CONTACT_15009]/her delegate.   
A DA assessment will also be performed at the Week 56/EOS visit; however, no study treatment will be administered.  
The different types of study visits are summarized in Table [ADDRESS_1176397].  
Table 6-3 Disease Activity assessment and treatment occurrence according to 
visit type 
Type  Study Period  DA Assessment  Treatment  
Baseline visit  TtC-Phase Yes Only if treatment was 
planned according to the individual TtC 
regimen of the core 
study  
Treatment visits  TtC-Phase  Yes Yes 
Inspection visits (optional)  TtC-Phase Yes 
Based on DA, as per investigator`s 
judgement  
Week 52/54*  TtC-Phase Yes Only if treatment was 
planned according to the individual TtC 
regimen  
ETD visit and EOS 
visit (Week 56 ) Follow -Up Yes No 
Brolucizumab should be administered in the study eye on the day of the study visit, or, if this is not possible, within 3 days after the occurrence of the study visit (except for Baseline / Day 1, in which case study treatment administration should occur within the next 24 hours) or no later than within the visit window (±14 days) as described in Section  [ADDRESS_1176398] occur after completion of the efficacy assessments described in Section  8.3 and pre -injection safety measures 
(tonometry, slit lamp and fundus examinations) described in Section  8.4. If study visit 
assessments and the corresponding treatment occur on separate days, a repeat safety checkup should be performed prior to treatment of the eye and results should be documented in the source documents.  
If any safety concern arises related to the study eye that, in the opi[INVESTIGATOR_871], may be further impacted by [CONTACT_213756], treatment needs to be cancelled.  
[COMPANY_001]  Confidential  Page 35 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 IVT injection is contraindicated in participants with active intraocular or periocular infections and in participants with active intraocular inflammation; therefore, the investigators must verify that these conditions are not present in the study eye prior to every injection.  Any adverse events 
must be recorded in the eCRF. 
If any sign of intraocular inflammation (IOI) is present, then an IVT injection must  not be 
performed. Additional ophthalmic examination and imaging should be performed to evaluate 
IOI, see Section  8.4 . 
If retinal vasculitis, and/or retinal vascular occlusion is confirmed, subjects must be 
discontinued from study treatment. In addition, subjects who experience IOI only (without RV and/or RO) may be at risk of developi[INVESTIGATOR_213722] /or retinal vascular occlusion and should be closely monitored and the investigator should evaluate the appropriateness of continuing further with study treatment. 
The IVT injection procedure, including aseptic and antimicrobial requirements, will be 
performed according to local clinical practice.  
7 Informed consent procedures  
Eligible participants may only be included in the study after providing (witnessed, where 
required by [CONTACT_6617]), IRB/IEC-approved informed consent. 
If applicable, in cases where the participants' representative(s) gives consent (if allowed 
according to local requirements), the participant must be informed about the study to the extent 
possible given his/her understanding. If the participant  is capable of doing so, he/she must 
indicate agreement by [CONTACT_30803]. 
Informed consent must be obtained before conducting any study- specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the participant source documents.  
[COMPANY_001]  will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH E6 GCP guidelines and regulatory requirements and is considered 
appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_6619]/IEC.  
Information about common side effects already known about the investigational drug can be found in the Investigator's Brochure (IB) and/or Core Data Sheet (CDS) for countries where brolucizumab is in the market.  This information will be included in the participant  informed 
consent and should be discussed with the participant  during the study as needed. Any new 
information regarding the safety profile of the investigational drug that is identified between IB updates will be communicated as appropriate, for example, via an investigator notification or an aggregate safety finding. 
The following informed consents are included in this study: 
• Main study consent, which also included:  
• A subsection that requires a separate signature [CONTACT_30833] ‘Optional Consent for 
Additional Research’ to allow future research on data/samples collected during this study. 
[COMPANY_001]  Confidential  Page 36 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 • As applicable, Pregnancy Outcomes Reporting Consent for female participants or the female partners of any male participants who took study treatment. 
Women of childbearing potential must be informed that taking the study treatment may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study , they must adhere to the contraception requirements . 
A copy of the approved version of all consent forms must be provided to [COMPANY_001]  after IRB/IEC 
approval. 
Participants might be asked to complete an optional questionnaire to provide feedback on their 
clinical trial experience.   
As new information becomes available, informed consent to be updated and then must be discussed with the participant.  
During the COVID- [ADDRESS_1176399] the 
informed consent discussion remotely (e.g. telephone, videoconference). Guidance issued by 
[CONTACT_213758] (e.g. the presence of an impartial witness, sign/dating separate ICFs by [CONTACT_6622], etc.). Remote informe d consent should be appropriately 
documented and confirmed by [CONTACT_846243]. 
8 Visit schedule and assessments 
The Assessment Schedule Table  8-1 lists all of the assessments and indicates with an “X” or 
“S” the visits when they are performed.  All data obtained from these assessments must be 
supported in the participant’s source documentation. 
Participants should be seen for all visits/assessments as outlined in the assessment schedule 
Table  8-1 or as close to the designated day/time as possible. Missed or rescheduled visits should 
not lead to automatic discontinuation. Participants who prematurely discontinue the study for any reason should be scheduled for a visit as soon as possible, at which t ime all of the 
assessments listed for the final visit will be performed. At this final visit, the adverse event and concomitant medications should be recorded on the CRF. 
If the COVID -19 pandemic limits or prevents on -site study visits, study treatment could not be 
administered and other study assessments may not be performed. Alternative methods of safety 
monitoring may be implemented. Depending on local regulations, site capabilities and patient’s visit status in the study, phone calls or virtual contacts (e.g. teleconsult) can be performed for safety follow -up for the duration of the pandemic, until it is safe for the participant to visit the 
site again.   
[COMPANY_001]  Confidential  Page 37 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Table 8-1 Assessment Schedule 
Period  Treat -to-Control phase  Follow -up 
Visit Name  [CONTACT_846252] 1  n2 W52/EOT3 ETD10 W56/EOS11 m12 
Visit Numbers1 1 110 120 130 130  
Weeks  1 2 to 50  52  56  
Informed consent  X        
Inclusion / Exclusion criteria  X         
Demography  X4         
Medical history/current medical 
conditions  X         
Prior/concomitant medication  X X X X X X 
Pregnancy Test  S4 S S S S  
Vital signs (sitting pulse and 
blood pressure)  X4 X X X X  
BCVA score (ETDRS)  X4 X X X X X 
Intraocular Pressure (IOP)  X4 X X X X  
Ophthalmic examination 5,[ADDRESS_1176400] injection        
Adverse Events  X X X X X X 
[COMPANY_001]  Confidential  Page 38 of 73 
Amended Protocol Version  02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Period  Treat -to-Control phase  Follow -up 
Visit Name  [CONTACT_846252] 1  n2 W52/EOT3 ETD10 W56/EOS11 m12 
Visit Numbers1 1 110 120 130 130  
Weeks  1 2 to 50  52  56  
 
1 Visit structure given for internal programming purpose only  
2 The number of weeks between visits will vary depending on the disease stability and length of intervals between injections as  determined by [CONTACT_846244]. Study treatment at the optional inspection visits ( [ADDRESS_1176401] injection when the interval is extended from 12 weeks to 16 weeks, and 16 weeks when the interval is extended from 16 to 20 weeks) is at the discretion of the 
investigator based on disease activity assessment.  
[ADDRESS_1176402] 
a planned injection visit on Week 54, unless the Week 52 visit is an inspection visit with injection administered.  
4 Assessments at the Week 64 (EOS) visit of the core study will be used as the baseline.  
5 May include visual acuity check, optic nerve perfusion, and tonometry, for safety assessment before and after IVT, as well as slit lamp examination, fundus examination 
before IVT. In case of an ocular AE, the assessments shall be recorded in the eCRF.  
6 Additional ophthalmic examinations and images will be performed in case of any signs of intraocular inflammation, retinal vasculitis and/or retinal vascular occlusion.  
[ADDRESS_1176403] injection (a window for the phone call is +14 days). From the second injection onwards, 
similar phone calls should be made at investigator’s discretion per local practice.  
10 ETD: Early treatment discontinuation applies to subjects who discontinue early from study treatment and continue in the study. This can occur at any time point. The 
assessments should be performed [ADDRESS_1176404] injection of study drug. For visits conducted after ETD and up to Week 56 (end of study) , while subject is on 
standard of care, only BCVA, new/any concomitant medications, and/or adverse events/ serious adverse events have to be recorded. Additional safety assessments and 
imaging can also be performed if required, as per investigators discretion. In addition, after ETD, subjects are not required to attend the mandatory visit at Week 52.  
[ADDRESS_1176405] undergone ETD 
assessments and continued in the study without study treatment.  
12 For subjects who continue in the study after ETD  and up to Week 56 (end of study) while subject is on standard of care. This can occur at any time point. Additional 
safety assessments and imaging can also be performed if required, as per investigators discretion. In addition, after ETD, subjects are not required to attend the 
mandatory visits at Week 52. The last visit should be at week 56.  
[COMPANY_001]  Confidential  Page 39 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 8.1 Screening  
8.1.1 Information to be collected on screening failures  
Participants who sign an informed consent form and subsequently found to be ineligible will be considered a screen failure. The reason for screen failure should be entered on the applicable Case Report Form. The demographic information, informed consent, and Inclusion/Exclusion pages must also be completed for screen failure participants. No other data will be entered into the clinical database for participants who are screen failures, unless the participant experienced a serious adverse event during the ev aluation of eligibility (see SAE Section  10.1.3 for reporting 
details).  
Participants who sign an informed consent and are considered eligible but fail to be started on treatment for any reason will be considered an early terminator. The reason for early termination should be captured on the appropriate disposition Case Report Form.  
8.2 Participant demographics/other baseline characteristics  
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with eCRF.  
Assessments performed at the Week 64 (EOS) visit of the core study will serve as the baseline for this extension study.  
The following information will be documented at baseline visit for each enrolled participant: 
• Age 
• Sex 
• Race/Ethnicity  
• Vital signs  
• Study eye 
• Visual acuity  
• Intraocular pressure  
• Ophthalmic examinations  
• Retinal imaging  
• Prior/Concomitant medications  
• Medical history and current medical conditions 
Investigators will have the discretion to record abnormal test findings on the medical history 
eCRF whenever, in their judgment, the test abnormality occurred prior to the informed consent signature.  
8.[ADDRESS_1176406] of brolucizumab on visual function, retinal structure and vascular leakage: 
• Best-corrected visual acuity with ETDRS- like charts  
[COMPANY_001]  Confidential  Page 40 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 • Anatomical retinal evaluation of SD -OCT images  
• Color Fundus Photography 
All efficacy assessments should be performed prior to any administration of study treatment.  
8.3.1 Visual acuity  
Visual acuity will be assessed in the study eye at every study visit and in the fellow eye at the baseline and Week 56/EOS visits using best correction determined from protocol refraction (BCVA). BCVA measurements will be taken in a sitting position using ETDRS –like visual 
acuity testing charts at an initial testing distance of 4 meters. The details of the refraction technique and VA testing, as well as training material, are provided in the applicable manual. Certification of the assessment procedures and assessors will occur prior to any evaluation of study participants. 
Participants at sites in some Asian countries will undergo BCVA testing using numerical charts 
rather than letter charts. Therefore, all references in the protocol to changes in letters read will be changes in numbers in these countries.  
8.3.2 Optical coherence tomography  
Spectral  Domain Optical Coherence Tomography (SD-OCT) images will be obtained and 
assessed in the study eye at every study visit and in the fellow eye at baseline and Week 56/EOS visits. Only SD -OCT machines can be used (i.e. no time-domain nor swept- source OCT).  
These assessments will be performed by a trained technician or investigator at the sites and should be performed after BCVA assessment and prior to any study drug administration. 
Investigators will evaluate the SD -OCT images to assess the status of disease stability. The SD -
OCT machine used for an individual participant should not change for the duration of the study.  
Central sub -field thickness (CSFT) will be measured by [CONTACT_66309] -OCT. The CSFT evaluated in this 
study represents the average retinal thickness of the circular area within [ADDRESS_1176407] angiography if available - imaging findings to inform 
his/her decision for treatment. However, their assessed findings of both quantitative and qualitative parameters will not be captured in the eCRF but must be included in the source documentation at the study site. 
A CRC will be used in this study. The CRC will provide sites with a Study Manual and training 
materials for the specified study ocular images. Before any study images are obtained, site personnel, test images, systems and software will be certified and val idated by [CONTACT_846245]. All SD-OCT and OCT angiography images will be obtained by [CONTACT_213761]- certified site personnel at the study sites. All SD -OCT  and OCT angiography 
[COMPANY_001]  Confidential  Page 41 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 images  will be forwarded to the CRC for independent standardized analysis, and be forwarded 
to [COMPANY_001] or Contract Research Organization (CRO) for storage.  
The CRC will create a database with the agreed variables as indicated in the CRC grading charter (a separate document) and will transfer the data from this database to [COMPANY_001] for analysis. The CRC data will be used for the evaluation of the objectives having SD -OCT and 
OCT angiography parameters to ensure a standardized evaluation. For further procedural details, the investigator  should refer to the applicable manual provided by [CONTACT_10186]. 
8.3.3 Color fundus photography and fluorescein angiography  
Color fundus photography (CFP) will be performed in the study eye at each scheduled injection visit, and in the fellow eye at baseline and Week 56/EOS visits.  
Fluorescein angiography (FA) will be performed in both eyes at baseline (captured at EOS of 
the core study) visit. FA may be performed at other visits at the investigator's discretion.  
Additional images will be taken in case of any signs of intraocular inflammation. OCT, CFP and FA (preferably wide -field or with peripheral sweeps) should be performed for safety 
evaluation, see Table  8-2.  
The investigator will evaluate the images according to their standard of clinical practice and may use any of the CFP imaging findings to inform his/her decision for treatment. However, their assessed findings of both quantitative and qualitative parameters will not be captured in the eCRF but must be included in the source documentation at the study site. 
All images , from scheduled and unscheduled visits, must be sent to the Central Reading Center 
(CRC). The CRC will provide sites with a Study Manual and training materials for the specified 
study ocular images. Before any study images are obtained, site personnel, te st images, systems 
and software will be certified and validated by [CONTACT_213760]. All 
CFP and FA images will be obtained by [CONTACT_213761]- certified site personnel at the study 
sites and forwarded to the CRC for independent standardized analysis and to [COMPANY_001] or a 
CRO for storage.  
The CRC will create a database with the agreed variables as indicated in the CRC grading charter (a separate document) and will transfer the data from this database to [COMPANY_001] for analysis. The  CRC data will be used for the evaluation of the objectives ha ving CFP 
parameters and their change over time as endpoints to ensure a standardized evaluation. For further procedural details, the investigator should refer to the applicable manual provided by [CONTACT_10186].  
8.3.[ADDRESS_1176408] assessments in this indication and are required for a comparative evaluation of this trial with the existing evidence from previous trials.  
Color fundus photography (CFP) is used to inspect retinal pathology. 
[COMPANY_001]  Confidential  Page 42 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 8.4 Safety  
Safety assessments will include vital signs, ophthalmic examinations, imaging and local 
laboratory evaluation (as per investigators ' discretion) as well as monitoring and recording type, 
frequency, and severity for all AEs. 
If the COVID -19 pandemic limits or prevents on -site study visits, phone calls or virtual contacts 
should be conducted for safety monitoring and discussion of the participant´s health status, until 
the participant can again visit the site.  
For details on monitoring, assessment and management of adverse events of inflammation, retinal vasculitis and/or retinal vascular occlusion, refer to  Section  10. For details on AE 
collection and reporting, refer to AE  Section 10.1. 
Safety assessments are specified below:  
Table 8-2 Safety assessments 
Assessment  Specification  
Vital signs  Vital signs include assessment of sitting blood 
pressure (systolic and diastolic pressure in 
mmHg) and pulse rate (beats per minute) and 
will be collected at all visits. 
On days when study drug is administered, vital 
signs will be measured before  administration of 
study medication. The results will be recorded in 
the eCRF.  
Ophthalmic exam  
and 
additional safety measures  The ophthalmic exam will consist of the 
following:  
Intraocular pressure  (IOP) will be assessed in 
the study eye, pre- dose and post -dose at every 
scheduled visit. The same method of tonometry 
has to be used through the whole study. In the 
fellow eye, IOP will be assessed at baseline and 
Week 56/EOS visit. The values recorded i n 
mmHg for either eye will be entered into the 
eCRF. Treatment and close monitoring of IOP 
should be performed by [CONTACT_213763]-transient elevation in intraocular pressure 
(≥ 25 mmHg). Intravitreal injection is not 
recomm ended unless normalization of the IOP 
has been achieved. Post -dose IOP should be 
assessed within 60 minutes after injection and if ≥ 25 mmHg, assessment should be repeated 
until back to normal. Monitoring of optic nerve 
head perfusion after injection may b e 
appropriate, at the discretion of the investigator 
and/or according to local requirements/practices. 
Results of these procedures will be recorded as 
appropriate in the source documents, and if the findings constitute an AE, it should be recorded 
in the e CRF.  
[COMPANY_001]  Confidential  Page 43 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Assessment  Specification  
Anterior biomicroscopy (slit lamp 
examination)  will be completed pre -dose at 
every scheduled and unscheduled visit to examine the anterior segment structures of the study eye (e.g., eyelids/lashes, conjunctiva, 
cornea, anterior chamber, iris, lens and anterior 
part of the vitreous). The fellow eye will be examined at baseline for eligibility, and at other 
visits at the discretion of the investigator. The results of the examination of either eye will be 
recorded in the source documents.  
Slit lamp examination must be carefully 
performed before each study treatment. If there 
are any signs of IOI, severity of anterior 
chamber cells and flare should be assessed according to the standardization of uveitis 
nomenclature (SUN) working group gradi ng 
system ( Jabs  et al 2005). The test results will be 
recorded in the source documents (e.g., ophthalmic examination tool) and captured in the appropriate eCRF as applicable.  
Posterior segment (indirect fundus) examination  will be conducted by [CONTACT_846246]. 
An examination of the peripheral retina must 
also be conducted to ensure that the intravitreal injection can safely be performed.  
Posterior segment examination must be 
performed carefully before each study treatment. The results of the examination including any 
abnormalities (e.g. vitreous cells/haze, retinal 
tear/detachment, hemorrhage and vascular occlusion, vasculitis, etc.) should be recorded in 
the source documents.  
If there are any signs of IOI, vitreous cells and 
haze should be assessed using National 
Institutes of Health (NIH) grading system 
(Nussenblatt  et al 1985). The outcome of the 
examination will be documented in the source 
document (e.g., ophthalmic examination tool) and appropriate eCRF page as applicable.  
Clinically significant abnormal findings from slit 
lamp or ophthalmoscopy observations should be 
recorded as an AE in the eCRF.  
[COMPANY_001]  Confidential  Page 44 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Assessment  Specification  
A phone call two weeks after the first injection (a 
window for the phone call is + 14 days)  must be 
made to check whether there are any changes in vision or any symptoms of intraocular inflammation. It should be documented in the 
source document and eCRF. From the second 
injection onwards, similar phone calls should be 
made at investigator’s discretion per local practice.  
In addition, instruct the patient to contact [CONTACT_846247]. Every effort should be 
made to bring the participant for immediate examination.   
Imaging:  When IOI, retinal vasculitis, and/or 
retinal vascular  occlusion is present or 
suspected during a visit, investigators must 
perform thorough ophthalmic examination, and 
conduct OCT, fluorescein angiography and color 
fundus photography (preferably wide- field or 
with peripheral sweeps). These additional 
assessme nts will be documented in the source 
and appropriate eCRF pages as applicable. The 
images are requested to be uploaded onto the 
CRC portal.  
Site visits for safety assessments (unscheduled visits) also can be made at any time during 
follow -up as needed.  
No central laboratory will support the study. However, investigators may at their discretion request laboratory tests, which should be performed by a local laboratory.  
8.4.[ADDRESS_1176409] be performed 
for confirmation; if the serum test is positive, the participant should discontinue study 
medication. Additional pregnancy testing might be performed if requested by [CONTACT_5277].  
Assessments of fertility  
Medical documentation of oophorectomy, hysterectomy, or tubal ligation must be retained as source documents. Subsequent hormone level assessment to confirm the woman is not of child -
bearing potential must also be available as source documentation in the following cases: 
1. Surgical bilateral oophorectomy without a hysterectomy 
2. Reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile.  
[COMPANY_001]  Confidential  Page 45 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 In the absence of the above medical documentation, FSH testing is required of any female participant regardless of reported reproductive/menopausal status at screening/baseline.  
8.4.[ADDRESS_1176410] for this indication/participant population.  
If there are any signs of IOI, additional assessment will be performed as described in Table  8-2 
and Section 10. 
8.5 Additional assessments 
No additional tests will be performed on participants entered into this study.  
9 Study discontinuation and completion 
9.1 Discontinuation and completion  
The investigator should discontinue study treatment for a given participant and/or withdraw the participant from the study if, on balance, he/she believes that continuation would be detrimental to the participant’s well-being. 
A participant will be considered to have completed the study when the participant has completed 
the last visit planned in the protocol. 
The investigator and/or referring physician will recommend the appropriate follow -up medical 
care, if needed, for all participants who are prematurely withdrawn from the study.  
9.1.[ADDRESS_1176411] discontinue study treatment for a given participant if he/she believes that continuation would negatively impact the participant's well -being. 
Study treatment must be discontinued under the following circumstances: 
• Subject requires treatment on a q4w interval  
• Subject develops retinal vasculitis and/or retinal vascular occlusion  
• Participant/guardian decision  
• Pregnancy 
• Use of prohibited treatment as per recommendations in the prohibited treatment section  
• Any situation in which study participation might result in a safety risk to the participant 
If discontinuation of study treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the participant’s premature discontinuation of study treatment and record this information.  
[COMPANY_001]  Confidential  Page 46 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Participants who discontinue study treatment or who decide they do not wish to participate in the study further should NOT be considered withdrawn from the study UNLESS they withdraw their consent (see 'Withdrawal of Informed Consent' Section  9.1.2). If they fail to return for 
these assessments for unknown reasons, every effort (e.g. telephone, e -mail, letter) should be 
made to contact [CONTACT_2299]/pre -designated contact [CONTACT_846248] -up 
Section  9.1.3. This contact [CONTACT_6636]. 
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact [CONTACT_6635], or with a person pre -designated by [CONTACT_2416]. This telephone contact [CONTACT_6636].  
After premature study treatment discontinuation, at a minimum, in abbreviated visits, the following data should be collected at clinic visits or via telephone/email contact:  
• New / concomitant treatments  
• Adverse Events / Serious Adverse Events  
• BCVA  
Additional safety assessments and imaging can be performed if required, as per investigator’s discretion.  
The investigator must also contact [CONTACT_6637]’s discontinuation from study treatment. 
Subjects must return [ADDRESS_1176412] study treatment to perform the Early Treatment 
Discontinuation (ETD). ETD assessments should be performed before start of standard of care treatment.  
• After these assessment s are performed, patient can be switch ed to standard of care (SOC) 
anti-VEGF IVT as per investigators discretion.  IVT injection is contraindicated in subjects 
with active intraocular or periocular infections and in subjects with active intraocular inflammation; therefore, the investigators must verify that these conditions are not present in the study eye prior to every injection.  
• Dosing of SOC and follow-up visits as per investigators discretion. Subjects are not required to attend the mandatory visit at W eek 52. The last visit should be at W eek 56. 
9.1.2 Withdrawal of informed consent  
Withdrawal of consent/opposition to use data/biological samples occurs when a participant: 
• Explicitly requests to stop use of their biological samples and/or data (opposition to use 
participant’s data and biological samples)  
and 
• No longer wishes to receive study treatment  
and 
• Does not want any further visits or assessments (including further study- related contacts)  
This request should be in writing (depending on local regulations) and recorded in the source 
documentation. 
[COMPANY_001]  Confidential  Page 47 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the participant’s decision to withdraw their consent/opposition to use data/biological samples and record this informa tion. 
Where consent to the use of Personal and Coded Data is not required in a certain country's legal framework, the participant therefore cannot withdraw consent. However, they still retain the 
right to object to the further collection or use of their Personal Data.  
Study treatment must be discontinued and no further assessments conducted, and the data that would have been collected at subsequent visits will be considered missing.  
Further attempts to contact [CONTACT_6639] -up. 
If the participant agrees, a final evaluation at the time of the participant’s withdrawal of consent/opposition to use data/biological samples should be made as detailed in the assessment table (refer to Section  8). 
[COMPANY_001] will continue to retain and use all research results (data) that have already been collected for the study evaluation, including processing of biological samples that has already started at time of consent withdrawal/opposition. No new Personal Data (including biological samples) will be collected following withdrawal of consent/opposition. 
9.1.[ADDRESS_1176413] show "due diligence" by [CONTACT_302014], e.g. dates of 
telephone calls, registered letters, etc. A participant should not be considered as lost to follow -
up until due diligence has been completed or until the end of the study. 
9.1.4 Early study termination by [CONTACT_30815].  
Reasons for early termination:  
• Unexpected, significant, or unacceptable safety risk to participants enrolled in the study 
• Decision based on recommendations from applicable board(s) after review of safety and 
efficacy data 
• Discontinuation of study drug development 
In taking the decision to terminate, [COMPANY_001]  will always consider participant welfare and safety. 
Should early termination be necessary, participants must be seen as soon as possible and treated 
as a prematurely withdrawn participant. The investigator may  be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the protection of the participant’s interests. The investigator or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.   
[COMPANY_001]  Confidential  Page 48 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 9.[ADDRESS_1176414] of care or other treatments, at the discretion of the investigator and/or referring physician, if needed.  
[ADDRESS_1176415], intraocular inflammation, including retinal vasculitis  
and/or r etinal vascular occlusion  please ensure compliance with the following:  
• A phone call two weeks after the first injection (window: +14 days) must be made to 
check whether there are any changes in vision or any symptoms of intraocular inflammation.  From the second injection onwards, similar phone calls should be made at 
investigator’s discretion per local practice  (Table 8 -2). 
• Instruct the patient to contact [CONTACT_213765] (refer to the optional patient brochure). Every 
effort should be made to bring the subject for immediate examination.  
• Close patient monitoring and thorough examination of the eye should be done to detect 
potential signs of inflammation ( Table 8 -2). 
• When IOI, retinal vasculitis, and/or retinal vascular occlusion is present or suspected during a visit, investigators must perform thorough ophthalmic examination, and will conduct OCT, fluorescein angiography and color fundus photography (preferably wide-field or with peripheral sweeps).  The images are requested to be uploaded onto the CRC 
portal.  
• If any sign of intraocular inflammation is present, an IVT injection must not be performed. Therefore investigators must verify that these conditions are not present in the study eye 
prior to every injection.  
• Subjects who experience intraocular inflammation only (without RV and/or RO) may be at risk of developi[INVESTIGATOR_213722]/or retinal vascular occlusion and should be closely monitored. The investigator should carefully evaluate the appropriateness of continuing further with study treatment. 
• If retinal vasculitis and/or retinal vascular occlusion is confirmed, subjects must  be 
discontinued from study treatment.  
• Participants should be treated for these events promptly according to clinical practice . 
10.1 Definition of adverse events and reporting requirements  
10.1.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical 
[COMPANY_001]  Confidential  Page 49 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has the responsibility for managing the safety of individual participant and identifying adverse events. 
[COMPANY_001]  qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.  
The occurrence of adverse events must be sought by [CONTACT_105]- directive questioning of the participant 
at each visit during the study. Adverse events also may be detected when they are volunteered 
by [CONTACT_6643], laboratory test findings, or other assessments.  
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to Section  10.1.2):  
1. The severity grade:   
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
2. Its relationship to the study treatment.  If the event is due to lack of efficacy or progression 
of underlying illness (i.e. progression of the study indication) the assessment of causality will usually be ‘Not suspected.’ The rationale for this guidance is  that the symptoms of a 
lack of efficacy or progression of underlying illness are not caused by [CONTACT_6645], they happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression of underlying disease can only be evaluated meaningfully by [CONTACT_6646], not on a single participant  
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not resolved must be reported  
4. Whether it constitutes a SAE (see Section  10.1.2 for definition of SAE) and which 
seriousness criteria have been met  
5. Action taken regarding with study treatment.  
All adverse events must be treated appropriately. Treatment may include one or more of the following:  
• Dose not changed 
• Dose Reduced/increased  
• Drug interrupted/withdrawn  
6. Its outcome  
Conditions that were already present at the time of informed consent should be recorded in medical history of the participant.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
[COMPANY_001]  Confidential  Page 50 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Adverse event monitoring should be continued for at least [ADDRESS_1176416] be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study), and assessment must be made at each visit (or more frequently, if necessary) of any changes in seve rity, the suspected relationship to 
the interventions required to treat it, and the outcome.  
Information about adverse drug reactions for the investigational drug can be found in the Investigator's Brochure (IB).  
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least one of the following criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically significant  
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_6533].  
10.1.2 Serious adverse events 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following 
criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the ICH-E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]:  
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition  
• elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
• social reasons and respi[INVESTIGATOR_6534]’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_201032] 51 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 • is medically significant, e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_157051]. Such events should be considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for al lergic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospi[INVESTIGATOR_6536]  (please refer to the ICH -
E2D Guidelines)). 
All new malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.  
Any suspected transmission via a medicinal product of an infectious agent is also considered a serious adverse reaction.  
10.1.[ADDRESS_1176417] be reported to 
[COMPANY_001]  safety immediately, without undue delay, under no circumstances later than within 24 
hours of  obtaining knowledge of the events (Note: If more stringent, local regulations regarding 
reporting timelines prevail). Detailed instructions regarding the submission process and requirements are to be found in the investigator folder provided to each site.  
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_6538], without undue delay, but under no circumstances later than within 24 hours of the investigator receiving the follow -up information (Note: If more stringent, local regulations 
regarding reporting timelines prevail). An SAE occurring at a different time interval or otherwise considered completely unrelated to a previously reported one must be reported separately as a new event.  
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new occurrence) and is thought to be related to the study treatment, a CMO & PS Department associate may urgently require further information from the investigator fo r health authority 
reporting. [COMPANY_001]  may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study with the same study treatment that this SAE has been reported. 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/[ADDRESS_1176418] study visit  should only be reported 
to [COMPANY_001] Safety if the investigator suspects a causal relationship to study treatment.  
[COMPANY_001]  Confidential  Page 52 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 10.1.[ADDRESS_1176419] be reported to [COMPANY_001]  within 24 hours of learning of its 
occurrence. The pregnancy should be followed up until birth  and one year after childbirth  to 
determine outcome, including spontaneous or  voluntary termination, details of the birth, and 
the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded and reported by [CONTACT_332028] (CMO&PS). Pregnancy follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment 
with any pregnancy outcome. Any SAE experienced during pregnancy must be reported. 
10.1.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or monitoring of a medicine while under the control of a healthcare professional, participant or consumer (EMA definition). 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be coll ected and reported in the 
safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse 
Treatment error type  Document in Dosing 
CRF (Yes/No)  Document in AE 
eCRF  Complete SAE form  
Unintentional study 
treatment error  Yes No No 
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.  
10.[ADDRESS_1176420] that allows its accurate reporting, interpretation, and verification.  
[COMPANY_001]  Confidential  Page 53 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Designated investigator staff will enter the data required by [CONTACT_5374] (eCRF). The eCRFs have been built using fully validated secure web-enabled software that conforms to [ADDRESS_1176421] been trained. Automatic validation programs check for data discrepancies in the eCRFs, allow modification and/or verification of the entered data by [CONTACT_6649].  
The investigator/designee is responsible for assuring that the data entered into eCRF is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate.  
After final database lock, the investigator will receive copi[INVESTIGATOR_6540].  
11.2 Database management and quality control  
[COMPANY_001]  personnel (or designated CRO) will review the data entered by [CONTACT_49432]. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies and missing  values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data. 
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Medical history/current medical conditions and adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Dates of visits and data about study treatments dispensed to the participant, will be tracked using an Interactive Response Technology (IRT). The system will be supplied by a vendor, who will also manage the database. The data will be sent electronically t o [COMPANY_001] (or a designated 
CRO) at specific timelines.  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked  and made available for data analysis. Any changes to 
the database after that time can only be made after written agreement by [CONTACT_654586]. 
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001]/delegated CRO representative will review the protocol and data capture requirements (i.e. eCRFs) with the investigators and their staff. During the study, Novar tis employs several 
methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of participant records, the accuracy of data capture / data entry, the adheren ce to the protocol and to Good Clinical 
Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor du ring these visits. Continuous remote monitoring of each site’s data 
[COMPANY_001]  Confidential  Page 54 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 may be performed by a centralized [COMPANY_001]/delegated CRO/CRA organization. Additionally, a central analytics organization may analyze data & identify risks & trends for site operational parameters, and provide reports to [COMPANY_001] clinical teams to assist w ith trial oversight.  
The investigator must maintain source documents for each participant in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the participant's file.  The investigator must also keep the original informed consent form signed by 
[CONTACT_2299] (a signed copy is given to the pa rticipant).  
The investigator must give the monitor access to all relevant source documents to confirm their consistency with the data capture and/or data entry. [COMPANY_001]  monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.  
[ADDRESS_1176422] deviation, quartiles, minimum and maximum. Categorical variables will be summarized with coun ts and percent in 
each category. Endpoints characterizing TtC regimen will be presented together with two -sided 
95% Confidence Intervals (CI). When appropriate, two -sided p- values will be presented as a 
descriptive statistics.   
All the endpoints, including the primary endpoint, are defined with respect to the study eye. 
Additional analysis may be also conducted to evaluate the impact of the COVID -19 pandemic  
and the urgent safety measure. In addition to the statistical methods outlined below, further details will be described in the 
statistical analyses plan (SAP).  
12.1 Analysis sets  
The following analyses sets are defined:  
The Enrolled Analysis Set  (EAS)  includes all participants who signed ICF and are assigned 
participant numbers. This analyses set will be used to summarize disposition of participants and pre-treatment adverse events.  
The Full Analysis Set (FAS) comprises all participants who received at least one dose of study treatment in the extension study. This set will serve as the primary analyses set for all efficacy and safety analyses.  
[COMPANY_001]  Confidential  Page 55 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 The Per -Protocol Set (PPS) is a subset of participants of the FAS with no protocol deviation 
with impact in the core study or the extension. The list of protocol deviations criteria will be provided in a separate document.  
12.2 Participant demographics and other baseline characteristics  
Demographic and other baseline data including disease characteristics will be listed and summarized descriptively in all participants for all analyses sets.  
Medical history (ocular and non- ocular) will be tabulated by [CONTACT_9313].  
Relevant medications and procedures will be summarized using number and percentage by [CONTACT_846249], and also listed by [CONTACT_514849]- ocular events. Other relevant baseline information will be 
listed and summarized with descriptive statistics as appropriate.  
12.3 Treatments  
The FAS will be used for the analyses described below.  
 
 
The duration to the treatment exposure will be summarized descriptively by [CONTACT_846250] 4 -week, 8- week, 12- week, 16- week and 20- week intervals at each 
visit. Frequency of selected treatment patterns will be shown. 
Percentages of participants who completed the study as per protocol without treatment 
discontinuation and interruptions will be summarized in all participants up to Week 56, and within the treatment intervals.  
Concomitant medications and significant non- drug therapi[INVESTIGATOR_846226] 56. 
12.4 Analysis of the primary endpoint(s)/estimand(s)  
The primary objectives of the study are: 
• To evaluate the extended durability of brolucizumab in a TtC regimen with respect to the 
duration of treatment intervals up to Week 56 
• To evaluate the functional outcomes of brolucizumab in a TtC regimen with respect to 
average change in BCVA at Week 52 and Week 56, i.e. change from the extension 
baseline to the average of Week 52 and Week 56 
12.4.1 Definition of primary endpoint(s)/estimand(s)  
The primary endpoints of the study are: 
• Duration of the last interval with no DA up to Week 56  
• Change in BCVA from extension baseline at Week 52 and Week 56 
Primary estimands along with the sensitivity estimands are in  Table 12-1. 

[COMPANY_001]  Confidential  Page 56 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Table 12-1 Primary and sensitivity estimands 
Endpoint  Estimand  Estimand 
definition  Analysis set  Data included in 
analysis  Statistical 
methods  
(including missing data 
strategy)  
Duration  
of last  
interval  
with no DA  Primary 
estimand [ADDRESS_1176423] interval 
with no DA that is 4/8/12/16/20 -
week intervals  FAS *Last interval 
with no DA up to Week 56  Two- sided 
95% Confiden
ce Interval of 
proportions. If 
there was DA, 
the last interval will be 
shortened by 
4 weeks, down to a 
minimum of 4 weeks  
[COMPANY_001]  Confidential  Page 57 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Endpoint  Estimand  Estimand 
definition  Analysis set  Data 
included in 
analysis  Statistical 
methods  
(including 
missing data 
strategy)  
Change  
in 
BCVA Primary estimand 2  Change in 
BCVA from 
extension 
Baseline at 
Week 52 and 
Week 56, i.e. the average 
difference in 
BCVA from extension 
Baseline over 
the period Week 52 
through Week 56  FAS All data 
collected until 
the participant 
discontinued 
study 
treatment and started SOC 
treatment(s)  
will be 
included.  Two- sided 
95% Confidence 
Interval 
obtained from 
ANCOVA with age at the 
baseline 
categories and BCVA at 
the baseline 
categories with (LOCF) 
imputation / 
replacement for missing 
data (e.g data 
unavailable due to lost to 
follow -up) / 
censored data 
(e.g. data 
unavailable 
due to use of 
alternative 
anti-VEGF)  
[COMPANY_001]  Confidential  Page 58 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Endpoint  Estimand  Estimand 
definition  Analysis set  Data 
included in 
analysis  Statistical 
methods  
(including 
missing data 
strategy)  
Duration of 
last interval 
with no DA 
excluding 
participants 
with protocol deviations 
with impact  Sensitivity estimand 1.[ADDRESS_1176424] interval 
with no DA 
that is 4/8/12/16/[ADDRESS_1176425] as 
per PPS  **PPS *Last interval with no DA up 
to Week 56  Two- sided 
95% Confiden
ce Interval of 
proportions.  If 
there was DA, the last interval will be 
shortened by 
4 weeks, down to a 
minimum of 4 weeks  
[COMPANY_001]  Confidential  Page 59 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Endpoint  Estimand  Estimand 
definition  Analysis set  Data 
included in 
analysis  Statistical 
methods  
(including 
missing data 
strategy)  
Change 
in BCVA 
excluding participants 
with protocol 
deviations 
with impact  Sensitivity estimand 2.1  Change in 
BCVA from 
extension Baseline at 
Week  52 and 
Week 56, i.e. 
the average 
difference in 
BCVA from extension 
Baseline over 
the period Week 52 
through Week 
56; excluding participants 
with protocol 
deviations with impact as 
per definition of PPS  **PPS All data 
collected  until 
the participant discontinued 
study 
treatment and started 
alternative 
treatment(s),  
will be 
included.  Two- sided 
95% Confidence 
Interval 
obtained from 
ANCOVA with age at the 
baseline 
categories and BCVA at 
the baseline 
categories and with 
(LOCF) 
imputation / replacement 
for missing 
data (e.g data unavailable 
due to lost to 
follow -up) / 
censored data 
(e.g. d ata 
unavailable due to use of 
alternative 
anti-VEGF).  
[COMPANY_001]  Confidential  Page 60 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Endpoint  Estimand  Estimand 
definition  Analysis set  Data 
included in 
analysis  Statistical 
methods  
(including 
missing data 
strategy)  
Duration of 
last interval 
with no DA excluding 
participants 
with protocol deviations 
with impact 
either in the core study or 
in the 
extension 
study  Sensitivity estimand 1.[ADDRESS_1176426] interval 
with no DA 
that is 4/8/12/16/[ADDRESS_1176427] 
either in the 
core or in the 
extension as 
per PPS  **PPS *Last interval with no DA up 
to Week 56  Two- sided 
95% Confiden
ce Interval of 
proportions.  If 
there was DA, the last interval will be 
shortened by 
4 weeks, down to a 
minimum of 4 weeks  
[COMPANY_001]  Confidential  Page 61 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Endpoint  Estimand  Estimand 
definition  Analysis set  Data 
included in 
analysis  Statistical 
methods  
(including 
missing data 
strategy)  
Change 
in BCVA 
excluding participants 
with protocol 
deviations with impact 
either in the 
core study, or in the 
extension study  Sensitivity estimand 2.2  Change in 
BCVA from 
extension 
Baseline at 
Week  52 and 
Week 56, i.e. 
the average 
difference in 
BCVA from extension 
Baseline over 
the period Week 52 
through Week 
56; excluding participants 
with protocol 
deviations with impact 
either in the 
core study or in the 
extension 
study as per 
definition of PPS **PPS All data 
collected  until 
the participant discontinued 
study 
treatment and started 
standard of 
care (SOC) treatment(s),  
will be 
included.  
Two- sided 
95% Confidence 
Interval 
obtained from 
ANCOVA with age at the 
baseline 
categories and BCVA at 
the baseline 
categories variables with 
(LOCF) 
imputation / replacement 
for missing 
data (e.g data unavailable 
due to lost to 
follow -up) / 
censored data 
(e.g. data 
unavailable due to use of 
alternative 
anti-VEGF).  
Proportion of 
participants 
with at least 16-weeks 
duration  
of last  
interval  
with no disease 
activity  Sensitivity estimand 1.[ADDRESS_1176428] interval with no 
disease 
activity that is at least16 -
weeks intervals up to 
Week 56  FAS *Last interval with no 
disease activity up to 
Week 56  
Two- sided 
95% Confiden
ce Interval of 
proportions.  If 
there was disease activity, the 
last interval 
will be shortened by 
4 weeks, 
down to a minimum of 4 
weeks  
[COMPANY_001]  Confidential  Page 62 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Endpoint  Estimand  Estimand 
definition  Analysis set  Data 
included in 
analysis  Statistical 
methods  
(including 
missing data 
strategy)  
Change in BCVA Sensitivity estimand 2.3  
Change in 
BCVA from 
extension 
Baseline at 
Week  52 and 
Week 56, i.e. 
the average 
difference in 
BCVA from extension 
Baseline over 
the period Week 52 
through Week 
56 FAS All data 
collected until 
the participant 
discontinued 
study 
treatment and started SOC 
treatment(s)  
will be 
included. Two- sided 
95% Confiden
ce Interval 
obtained 
based on 
mixed effects models with 
age at the 
baseline categories 
and BCVA at 
the baseline 
categories  
Proportion of 
participants 
with at least 
16-weeks 
duration of 
last interval 
with no 
disease 
activity excluding 
participants 
with important protocol 
deviations  Sensitivity estimand 1.[ADDRESS_1176429] 16-
weeks 
intervals at Week 56, 
excluding 
participants with important 
protocol 
deviations as 
per PPS  PPS**  *Last interval with no 
disease 
activity up to 
Week 56  Two- sided 
95% Confiden
ce Interval of 
proportions.  If 
there was 
disease 
activity, the 
last interval 
will be shortened by 
4 weeks, 
down to a minimum of 4 
weeks  
[COMPANY_001]  Confidential  Page 63 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Endpoint  Estimand  Estimand 
definition  Analysis set  Data 
included in 
analysis  Statistical 
methods  
(including 
missing data 
strategy)  
Proportion of 
participants 
with at least 
16-weeks 
duration of the last interval with no 
disease 
activity excluding 
participants 
with important protocol 
deviations 
either in the core study or 
in the 
extension 
study  Sensitivity 
estimand 1.[ADDRESS_1176430] 16-
weeks 
intervals, excluding 
participants 
with important protocol 
deviations 
either in the core or in the 
extension as per PPS PPS**  *Last interval 
with no 
disease 
activity up to 
Week 56  Two- sided 
95% Confiden
ce Interval of 
proportions.  If 
there was disease activity, the 
last interval 
will be shortened by 
4 weeks, 
down to a minimum of 4 
weeks  
*: If the duration of the last interval  falls within the following ranges of [q4w, q8w) or [q8w, q12w), 
[q12w, q16w), [q16w, q20w) or ≥ q20w then the floor value of these ranges i.e. q4w, q8w, q12w, q16w, 
q20w, respectively, will be used for imputation.  
  
**: Patients who take prohibited concomitant medication are already excluded from PPS as taking 
prohibited medication is considered a deviation with impact.  
12.4.2 Statistical model, hypothesis, and method of analysis 
The average change in BCVA from extension baseline at Week  52 and Week 56 will be 
estimated in Analyses of Covariance (ANCOVA) with baseline age categories and baseline 
BCVA categories. The estimate of BCVA change will be accompanied by 95%  CI. 
The distribution of the last interval with no DA up to Week 56 will be described based on counts and proportions of participants at 4- week, 8- week, 12- week, 16- week, and 20- week intervals. 
The proportions will be accompanied by 95% Confidence Intervals (CI ). 
12.4.[ADDRESS_1176431] (LOCF) method. Observed values from both scheduled and unscheduled visits will be used for the LOCF imputation. 
[COMPANY_001]  Confidential  Page 64 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 For participants who discontinue treatment but continue in the study, the BCVA data will be censored at the time the participant started Standard of Care treatment in the study eye.  
12.4.[ADDRESS_1176432] interval will be shortened by 4 weeks down to a minimum of 4 weeks.  
Missing BCVA values for reasons other than specified in Section  12.4.3 will also be imputed 
using LOCF method. 
12.4.5 Sensitivity analyses for primary endpoint/estimand 
Sensitivity analyses to examine robustness with respect to protocol deviations will be performed 
based on the PPS. 
Sensitivity analyses will be performed in a subset excluding participants with protocol 
deviations with impact either in the core study, or in the extension study. 
To evaluate robustness of the analyses based on the LOCF method, sensitivity analyses will be 
performed on the observed data in the FAS and mixed models for repeated measures ( MMRM). 
Sensitivity estimands in exposed and non- exposed to the  urgent  safety measures : As a 
sensitivity analyses, the proportion of participants with at least 16- weeks as the last interval 
with no disease activity at Week [ADDRESS_1176433] - the urgent safety 
measures were introduced . The estimates of proportions will be accompanied by 95% CI 
obtained using Goodman (1965) . The analyses will be performed FAS and PPS (excluding 
participants with important protocol deviations in the extension study and either in the core study or in the extension study). 
12.5 Analysis of secondary endpoints/estimands  
12.5.1 Efficacy and/or pharmacodynamic endpoint(s)  
FAS will be used to analyze durability, functional and anatomical outcomes. 
To evaluate the anatomical outcomes of brolucizumab in all patients and per randomized arm 
in the core study 
• Change in CSFT from extension baseline to Week 52 and Week 56  
• Number of visits with presence of IRF and/or SRF, and sub- RPE fluid in the central 
subfield as assessed by [CONTACT_66309] -OCT at Week 52 and Week 56  
To assess the durability of brolucizumab in all patients and/or per randomized arm in the core 
study 
• Duration of the last interval with no DA up to Week 56 
• Duration of the maximal intervals with no DA up to Week 56 
• Change of the duration of last interval with no DA between extension baseline and Week 
56  
[COMPANY_001]  Confidential  Page 65 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 To assess the functional outcomes of brolucizumab per randomized arm in the core study  
• Change in BCVA from extension baseline to Week 52 and Week 56  
Counts and proportions for the endpoints describing durability, tolerability and anatomical 
outcomes (i.e. number of visits with presence of IRF and/or SRF) will be accompanied by [CONTACT_1192] -
sided 95% CI inferred based on binomial distribution for each endpoint and two- sided 95% 
simultaneous C Is inferred using the  Goodman method ( Goodman 1965).The Goodman method 
is used for obtaining simultaneous confidence intervals (might be better than single binomial 
confidence intervals) for the parameters of a multinominal distribution, for example for a 
multinomial endpoint (4 -week interval, 8 -week inte rval, 12 -week interval, 16- week interval, 
and 20- week interval).  These analyses will be performed for all participants.  
For the analyses of functional and anatomical outcome (i.e. change in CSFT) the 95%  CI will 
be inferred based on ANOVA analyses.  
12.5.2 Safety endpoints 
The following endpoints assess the safety  of brolucizumab  
• Occurrence of Ocular and Non -ocular AEs up to Week 56 
For all safety analyses, the FAS will be used. All listings and tables will be presented in all participants.  
Safety summaries (tables, figures) include only data from the on -treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change from baseline summaries). In addition, a separate summary for death will be provided. In particular, summary tables for adverse events (AEs) will summarize only on -treatment events, with a start 
date during the on- treatment period.  A separate summary table will be provided for AEs of 
study eye, fellow eye and non- ocular AEs. 
The on- treatment period lasts from the date of first administration of study treatment to [ADDRESS_1176434] administration of study treatment (EOT) or EOS whichever is the latest.  
Adverse events 
Treatment emergent AEs are defined as AEs which start on or after the time of the first injection 
of study treatment in this extension study and until the patient exits the study. AEs which start 
prior to the date/time of the first injection of study treatment in this extension study will be listed only. Treatment emergent AEs occurring during the last 6 months of the core study, for the same set of participants included in the exte nsion study safety set will be presented. All 
treatment emergent SAEs/AEs as  documented in the core study will be listed as medical history.  
The number (and percentage) of participants with treatment emergent adverse events (events started after the first dose of study medication or events present prior to start of the extension study but increased in severity based on preferred term) will be s ummarized in the following 
ways:  
• by [CONTACT_168322].  
• by [CONTACT_92869], preferred term and maximum severity.  
• by [CONTACT_846251] (SMQ) and preferred term.  
[COMPANY_001]  Confidential  Page 66 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Separate summaries will be provided for study medication related adverse events, death, serious adverse events, other significant adverse events leading to discontinuation.  
The number (and proportion) of participants with adverse events of special interest will be 
summarized.  
A participant with multiple adverse events within a primary system organ class is only counted once towards the total of the primary system organ class.  
Adverse events which will be counted for a specific treatment period (i.e. baseline to Week 52) are those which are treatment -emergent. These events are those with an onset after the start of 
the treatment period, or which were present prior to the start of the treatment period but increased in severity, changed from being not suspected to being suspected of study drug relationship, or developed into SAEs after the start of the treatment period.  
Vital signs  
Clinically relevant abnormalities in vital signs data will be listed by [CONTACT_30827]/time and if ranges are available, abnormalities will be flagged. Summary statistics will be provided by [CONTACT_765]/time.  
12.[ADDRESS_1176435] deviation of the change in BCVA of 13, the 95% Confidence Interval  (CI) of 
the change is estimated to be ( -2.1, 0.13) assuming the observed change is -1. 

[COMPANY_001]  Confidential  Page 67 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Table 12-2  shows the distribution of duration as estimated based on simulation studies along 
with precision as estimated based on the simulations . Table 12-3 shows width of 95% CI as 
estimated based on a sample size (number of participants completing the extension study) varying from 503 to 100. The numbers are chosen based on assuming that  90% / 80% / 70%  / 
etc. of participants from the core study enter the extension and also assuming that 10% / 20 % 
/ 30 %  / etc of participants drop out reaching EOS of the extension. Similarly,  Table 12 -4 shows 
95% CI for the estimate in the change in BCVA, assuming that the observed change is - [ADDRESS_1176436] deviation of the change is 13. 
For example, when the number of participants completing the extension study decreases from 
503 to 250, width of the 95% CI increases from 5.8% to 8.3 % for the estimated proportion of 
12.7% participants being on the 16- weeks interval; and from 6.9% to 9.8% for the estimated 
proportion of 19.4% of participants being on 20 -weeks intervals. With the same reduction in 
the sample size, the 95% CI for the est imated change in BCVA goes from ( -2.1, 0.14) to ( -2.6, 
0.62).  
Table 12-2 Duration of intervals as estimated based on simulation studies  
Interval 
duration  4-weeks  8-weeks  12-weeks 16-weeks 20-weeks 
Frequency (SD as assessed by 
[CONTACT_102143])  8.6% (1.7%)  30.2%  (1.9%)   29.2%  (2.3%)  12.7%  (1.7%)  19.4% (2.4%)  
Table 12-3 Duration of intervals as estimated based on simulation studies and width 
of 95%  Confidence Interval 
Duration of the treatment 
interval  4-weeks  8-weeks  12-weeks  16-weeks  20-weeks  
Frequency  
(SD from simulations)  8.6%  
(1.7%)  30.2%  
(1.9%)  29.2%  
(2.3%)  12.7%  
(1.7%)  19.4%  
(2.4%)  
N of participants 
completing the 
extension study  Width of 95% Confidence Interval  
503 4.9%  8.0%  7.9%  5.8%  6.9%  
447 5.2%  8.5%  8.4%  6.2%  7.3%  
391 5.6%  9.1%  9.0%  6.6%  7.8%  
447 5.2%  8.5%  8.4%  6.2%  7.3%  
398 5.5%  9.0%  8.9%  6.5%  7.8%  
348 5.9%  9.6%  9.6%  7.0%  8.3%  
391 5.6%  6.6%  9.0%  6.6%  7.8%  
348 5.9%  9.6%  9.6%  7.0%  8.3%  
304 6.3%  10.3%  10.2%  7.5%  8.9%  
250 7% 11.4%  11.3%  8.3%  9.8%  
[COMPANY_001]  Confidential  Page 68 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 200 8.3%  13.1%  13.0%  9.7%  11.4%  
170 9.0%  14.3%  14.2%  10.6%  12.4%  
150 9.6%  15.2%  15.1%  11.3%  13.2%  
120 10.9%  17.1%  16.9%  12.7%  14.9%  
100 12.0%  18.8%  18.6%  14.0%  16.3%  
Table 12-4 95% Confidence Interval for BCVA change assuming SD of the change 
is 13. 
N of participants completing the extension 
study  95% Confidence Interval of BCVA change 
assuming the observed change is -1. 
503 (-2.1, 0.14)  
447 (-2.2, 0.21)  
391 (-2.3, 0.29)  
447 (-2.2, 0.21)  
398 (-2.3, 0.28)  
348 (-2.4, 0.37)  
391 (-2.3, 0.29)  
348 (-2.4, 0.37)  
304 (-2.5, 0.47)  
250 (-2.6, 0.62)  
200 (-2.8, 0.81)  
170 (-3.0, 0.97)  
150 (-3.1, 1.1)  
120 (-3.4, 1.4)  
100 (-3.6, 1.6)  
13 Ethical considerations and administrative procedures 
13.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical principles laid  down in the Declaration of Helsinki. 
13.2 Responsibilities of the investigator and IRB/IEC  
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_30757]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, participa nt recruitment procedures (e.g., 
advertisements) and any other written information to be provided to participants. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and 
[COMPANY_001]  Confidential  Page 69 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001]  Quality Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs, and regulatory authorities as required. If an inspec tion of the clinical site is 
requested by a regulatory authority, the investigator must inform [COMPANY_001]  immediately that this 
request has been made.  
13.[ADDRESS_1176437]. In addition, after study completion (defined as last patient last visit) and finalization of the study report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the [COMPANY_001] clinical trial results website and all required Health Authority websites (e.g. Clinicaltrials.gov, EudraCT etc.).  
For details on the [COMPANY_001]  publication policy including authorship criteria, please refer to the 
[COMPANY_001]  publication policy training materials that were provided to you at the trial investigator 
meetings.  
13.[ADDRESS_1176438] Quality Management System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard Operating Procedures (SOPs) as well as applicable global/local GCP regula tions and ICH 
Guidelines. 
Audits of investigator sites, vendors, and [COMPANY_001]  systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality control of the 
clinical trial. The clinical audit process uses a knowledge/risk -based approach.  
Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols and internal SOPs, and are performed according to written [COMPANY_001] processes.  
[ADDRESS_1176439] be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_76644] 70 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 [COMPANY_001]  and approved by [CONTACT_1201]/IEC and Health Authorities, where required, it cannot be 
implemented.  
14.[ADDRESS_1176440] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any participant  included in this 
study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
[COMPANY_001]  Confidential  Page 71 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 [ADDRESS_1176441] . 
Blinder KJ, Bradley S, Bressler NM, et al (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age- related macular degeneration: TAP and VIP report no. 1. 
Am. J Ophthalmol; 136(3):407-18 
Bloch SB, Larsen M, Munch IC (2012) Incidence of legal blindness from age- related macular 
degeneration in Denmark: year 2000 to 2010. Am. J Ophthalmol; 153:209–13. 
Campbell JP, Bressler SB, Bressler NM (2012) Impact of availability of anti -vascular 
endothelial growth factor therapy on visual impairment and blindness due to neovascular age-
related macular degeneration. Arch Ophthalmol; 130(6):794 -5. 
DeCroos FC, Reed D, Adam MK, et al (2017) Treat-and-Extend Therapy Using Aflibercept for Neovascular Age- related Macular Degeneration: A Prospective Clinical Trial. Am J 
Ophthalmol; 180:142–50. 
Ferris FL (1983) Senile macular degeneration: review of epi[INVESTIGATOR_258387]. Am. J 
Epi[INVESTIGATOR_5541]; 118(2):132 -51.  
Ferris FL, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol; 102:1640 2. 
Gillies MC, Hunyor AP, Arnold JJ, et al (2019) Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age- Related Macular 
Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol; 137(4):372-79.  
Goodman, LA (1965) On Simultaneous Confidence Intervals for Multinomial Proportions. 
Technometrics; 7(2):247-54.  
Guymer RH, Markey CM, McAllister IL, et al (201 9) Tolerating Subretinal Fluid in 
Neovascular Age- Related Macular Degeneration Treated with Ranibizumab Using a Treat -
and-Extend Regimen: FLUID Study 24- Month Results. Ophthalmology; 126:723- 34.  
Jabs DA, Nussenblatt RD, Rosenbaum DT (2005) Standardization of uveitis nomenclature 
(SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol; 140:509 16.  
Kertes PJ, Galic IJ, Greve M, et al (2019) Canadian Treat -and- Extend Analysis Trial with 
Ranibizumab in Patients with Neovascular Age- Related Macular Disease: One- Year Results 
of the Randomized Canadian Treat -and-Extend Analysis Trial with Ranibizumab Study. 
Ophthalmology; 126:841-48.  Lim LS, Mitchell P, Seddon JM, et al (2012) Age- related macular degeneration. Lancet; 
379:1728–38.  
Miller JW (2013) Age- related macular degeneration revisited --pi[INVESTIGATOR_846227]: the LXIX 
Edward Jackson memorial lecture. Am J Ophthalmol; 155:1 –35.
 
[COMPANY_001]  Confidential  Page 72 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 Nussenblatt RB, Palestine AG, Chan CC, et al (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology; 92(4):467 -71. 
Ohji M, Takahashi K, Okada AA, et al (2020) Efficacy and Safety of Intravitreal Aflibercept Treat -and-Extend Regimens in Exudative Age- Related Macular Degeneration: 52 - and 96-
Week Findings from ALTAIR: A Randomized Controlled Trial. Adv Ther; 37:1173–87.  
Shah AR, Del Priore  LV (2007) Progressive visual loss in subfoveal exudation in age- related 
macular degeneration: a meta -analysis using Lineweaver-Burke plots. Am J Ophthalmol; 
143:83 89. 
Shah AR, Del Priore LV (2009) Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology; 116:1901-7. 
Silva R, Berta A, Larsen M, et al (2018) Treat -and-Extend versus Monthly Regimen in 
Neovascular Age- Related Macular Degeneration: Results with Ranibizumab from the 
TREND Study. Ophthalmology; 125:57-65.  
Spi[INVESTIGATOR_258390] K, Garrett KL, Shen WY, et al (2000) Overexpression of vascular endothelial 
growth factor (VEGF) in the retinal pi[INVESTIGATOR_846228]. Am. J. Pathol ; 157(1):  135- 44. 
Wong WL, Su X, Li X, et al (2014) Global prevalence of age- related macular degeneration 
and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health; 2: e106 16. 
Wykoff CC, Croft DE, Brown DM, et al (2015) Prospective Trial of Treat-and- Extend versus 
Monthly Dosing for Neovascular Age- Related Macular Degeneration: TREX -AMD 1 -Year 
Results. Ophthalmology; 122(12): 2514-22. 
Wykoff CC, Ou WC, Brown DM, et al (2017) Randomized Trial of Treat-and- Extend versus 
Monthly Dosing for Neovascular Age- Related Macular Degeneration: 2 -Year Results of the 
TREX -AMD Study. Ophthalmol Retina; 1(4): 314 -321. 
[COMPANY_001]  Confidential  Page 73 of 73 
Amended Protocol Version 02 (clean )  Protocol No. CRTH258A2303E1  
 
 
 16 Appendices  
Not applicable 